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ABSTRACT OF THE DISSERTATION 
 
The role of astrocyte activation in infantile neuronal ceroid lipofuscinosis (INCL) 
by 
Shannon Lynn Macauley-Rambach 
Doctor of Philosophy in Biology and Biomedical Sciences (Neurosciences) 
Washington University in St. Louis 
Dr. Mark S. Sands, Chairperson 
 
Infantile neuronal ceroid lipofuscinoses (INCLs), or Batten Disease, is an 
inherited neurodegenerative lysosomal storage disorder affecting the central 
nervous system (CNS) during infancy or childhood.  Hallmark pathological 
changes include accumulation of autofluorescent material, neuronal loss, cortical 
thinning, and brain atrophy, which ultimately lead to cognitive deficits, motor 
dysfunction, seizure activity, and blindness.  INCL is the result of mutations in the 
CLN1 gene leading to a deficiency in the lysosomal enzyme, palmitoyl protein 
thioesterase 1 (PPT1).  A mouse model of INCL, the PPT1-deficient (PPT1-/-) 
mouse, was recently created by a targeted disruption in the CLN1 gene.  The 
phenotype of the PPT1-/- mouse is similar to that found in human INCL patients, 
suggesting the PPT1-/- mouse is an authentic model of INCL.  Although the 
clinical symptoms of disease are well described, the cellular mechanisms 
underlying these pathological changes and functional deficits remain poorly 
understood. Therefore, the first goal of this dissertation was to investigate the 
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temporal-spatial progression of disease in a mouse model of INCL.  We 
demonstrated a profound neuronal and glial involvement underlying both 
physiological and functional deficits.  From these studies, we also found the first 
pathological change observed was the upregulation of glial fibrillary acidic protein 
(GFAP), a marker of astrocyte activation, in the thalamus, cortex, and 
cerebellum.  Focal regions of GFAP upregulation were an accurate predictor of 
future sites of neuronal loss.  Since astrocyte activation is both helpful and 
harmful to an injured CNS, the second aim of this dissertation was to investigate 
the role of astrocyte activation in a mouse model of INCL using the GFAP-/-, 
Vimentin-/- mice.  We demonstrated that astrocyte activation, as defined by 
GFAP upregulation, plays a protective role in INCL. 
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INTRODUCTION 
Lysosomal Storage Diseases: An Overview 
 Lysosomal storage diseases (LSDs) are a group of rare, inherited 
disorders involving both the visceral tissues and central nervous system (CNS) of 
affected patients (Hers, 1965; Neufeld, 1991).  There are greater than 45 distinct 
metabolic disorders in total. LSDs affect approximately 1 in 5,000 live births, 
making these disorders one of the most common childhood genetic diseases 
(Meikle et al., 1999).  
Each LSD is a discrete genetic disorder caused by a single gene mutation.  
In all cases, the genetic mutation of a particular protein causes a disruption in 
normal lysosomal function (Scriver, 2001).  Most of the disorders are transmitted 
through autosommal recessive inheritance, but a subset of LSDs is X linked. The 
main function of the lysosome is the degradation of macromolecules into simpler 
metabolites.  Most LSDs are due to defects in soluble lysosomal enzymes that 
are responsible for the catabolism of macromolecules.  The mutations lead to the 
reduction (>90%) or complete ablation of enzyme activity for that specific protein.  
The remainder of LSDs is caused by mutations in key lysosomal membrane 
proteins, proteins involved in lysosomal enzyme trafficking, or proteins 
responsible for lysosomal enzyme activation (Neufeld, 1991; Winchester, 2004).  
Regardless of the function of a given protein, most LSDs result in the 
accumulation of undigested substrates in the lysosomal compartment.  As the 
undegraded product steadily accumulates within the organelle, both the size and 
number of lysosomes within a cell increases.  Upon microscopic inspection, this 
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lysosomal accumulation gives the cell 
and its cytoplasm a “foamy” 
appearance; a hallmark characteristic 
of LSD pathology (Figure 1).  Although 
the mechanism is still unknown 
(Ballabio and Gieselmann, 2009), 
accumulated substrates interfere with 
normal cellular processing, ultimately affecting the function of vital organs such 
as the brain, kidneys, liver, lungs, spleen, and heart (Macauley and Sands, 
2009b; Neufeld, 1991; Scriver, 2001).  The clinical signs associated with LSDs 
can include organomegally, skeletal deformities, pulmonary insufficiencies, 
immunologic abnormalities and cardiac defects.   In addition to these systemic 
problems, CNS involvement occurs in 75% of all LSDs.   This subset of affected 
patients present with some or all of the following neurologic symptoms: 
developmental regression, visual and hearing deficits, mental retardation, 
seizures, motor deficits, speech impairment, and other behavioral abnormalities 
(Hoffmann and Mayatepek, 2005; Sands and Haskins, 2008; Walkley, 1998).  
LSDs can affect patients as early as within the first year of life, or alternatively, 
they can present in adulthood.  Regardless of onset, each disorder is progressive 
in nature, with a complex set of clinical maladies and ultimately premature death. 
Figure 1. Lysosomal accumulation in a 
model of LSD.  Notice the lysosomal 
accumulation and distension (arrows) in a 
diseased neuron (B) compared to a WT 
neuron (A).    
A B 
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Neuronal Ceroid Lipofuscinoses (NCLs) 
Neuronal ceroid lipofuscinoses (NCLs), or Batten Diseases, are a group of 
autosomal recessive lysosomal storage disorders (LSDs) typified by prominent 
CNS involvement.  As a class of disorders, the overall incidence is approximately 
1:12,500 live births and represents the most common inherited pediatric 
neurologic disorders worldwide (Bennett and Hofmann, 1999; Goebel and 
Wisniewski, 2004; Hofmann and Peltonen, 2001).  Classification of these 
disorders was historically based on the age of onset.  Infantile (INCL), late-
infantile (LINCL), and juvenile (JNCL) forms referred to cases affecting children; 
however, rare forms with an adult onset (ANCL) were also described.  Recently, 
the use of modern genetic tools has led to a more accurate classification of the 
various forms of NCL. To date, there are eight different forms of Batten Disease 
resulting from mutations in separate genes, CLN1 through CLN8 (Cooper, 2003; 
Goebel and Wisniewski, 2004).  Although the metabolic function of many of these 
gene products remains unclear, it is known that CLN1, CLN2, and CLN5 encode 
soluble lysosomal enzymes while the remaining CLN genes encode lysosomal 
membrane proteins.   
Although the age of onset, disease progression, and age of death vary in 
each form of NCL, there are characteristics common to all forms of NCL.  The 
clinical course of disease is progressive and includes blindness, epilepsy, mental 
retardation, and motor deficits (Hofmann and Peltonen, 2001; Rider and Rider, 
1988; Santavuori, 1988; Santavuori et al., 1974).  A histological finding common 
to all the NCLs is the intracellular accumulation of autofluorescent substrates.  To 
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date, the composition of this storage product remains largely unknown.  The 
accumulation of storage material coincides with pathological changes such as 
widespread neuronal loss, retinal degeneration, cortical thinning, and overall 
brain atrophy (Wisniewski et al., 1988).  More recently, astrocyte proliferation and 
microglia activation were described in both patients with NCL and animals 
models of disease.  Although the CNS pathology and functional impairment is 
well documented in these diseases, it still remains unclear how the two are 
related.   
 
Infantile Neuronal Ceroid Lipofuscinosis (INCL) 
 Of the eight distinct genetic variants currently described, infantile neuronal 
ceroid lipofuscinosis (INCL) is the most rapidly progressing form of NCL 
(Hofmann et al., 1999; Hofmann and Peltonen, 2001; Vesa et al., 1995).  
Clinically, patients with INCL appear asymptomatic at birth and development 
proceeds normally until 6-12 months of age.  By 12 months of age, affected 
children begin to show signs of developmental regression, including mental 
retardation, microcephaly, and motor deficits (Hofmann et al., 1999; Hofmann 
and Peltonen, 2001; Santavuori et al., 1974; Vesa et al., 1995).  Visual 
impairment is often the first clinical sign of INCL.  Typically, visual defects 
emerge about one year of age, which lead to blindness by age 2.  Myoclonic 
jerks appear between 16 to 24 months of age, which is concurrent with changes 
in electroencephalography (EEG).  Specifically, there is decreased amplitude or 
flattening of background EEG activity by 2 years of age, which progresses to an 
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inactive EEG by 3-4 years of age (Haltia et al., 1973a; Haltia et al., 1973b; Haltia 
et al., 1995; Hofmann and Peltonen, 2001; Vanhanen et al., 1997).  The average 
age of death is 6 years of age, but some children survive until adolescence. 
 At autopsy, the CNS pathology is remarkable (Haltia et al., 1973a; Haltia 
et al., 1973b; Haltia et al., 1995; Hofmann and Peltonen, 2001; Vanhanen et al., 
1997).  There is an overall brain atrophy, mostly due to thinning of the cerebral 
cortex.  The cerebral cortex is denuded of neurons and replaced by 
macrophages, activated microglia and reactive astrocytes.  The cerebellar cortex 
is also atrophic due to a loss of both granule cells and Purkinje cells.  Neuronal 
cell loss is present in subcortical structures, with the thalamus most severely 
affected and the brain stem, hypothalamus, and subthalamus relatively spared.  
In addition to the neurodegeneration and astrocytosis in the cerebrum and 
cerebellum, there is a nearly complete loss of myelin at the end stage of disease, 
with myelin levels being 2% of normal.    
The cellular pathology underlying the gross anatomical changes is severe 
as well.  Like other forms of NCL, autofluorescent accumulation is a hallmark of 
INCL.  The storage product, when examined by electron microscopy, is 
composed of granular osmiophilic deposits (GRODs) localized to the lysosome.  
Although the exact composition of GRODs is poorly understood, biochemical 
studies identified the storage material to be 43% protein and 35% lipid.  Of the 
proteins extracted, three major products were identified- Saposins A and D 
(SAPs A and D) and glial fibrillary acidic protein (Haltia et al., 1995; Tayama et 
al., 1992; Tyynela et al., 1993).  Interestingly, the major constituent of storage 
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accumulation in other NCLs, subunit C of mitochondrial ATPase (Palmer et al., 
1992), is not found in GRODs from INCL patients.  Although it is important to 
identify the storage products within disease cells, the role SAP A and D or GFAP 
plays in disease pathogenesis remains unknown.   
Infantile neuronal ceroid lipofuscinosis is the result of mutations in the 
CLN1 gene, which encodes the lysosomal enzyme, palmitoyl protein thioesterase 
1 (PPT1; (Das et al., 1998; Hofmann et al., 2002; Mitchison et al., 1998; 
Mitchison et al., 2004; Vesa et al., 1995).  The human cDNA encoding PPT1 
consists of a 918 base pair open reading frame flanked by a short 14 base pair 
5’-untranslated region and a 1388bp 3’-untranslated region (Camp et al., 1994; 
Hofmann and Peltonen, 2001).  In the 306 amino acid residues of the human 
protein, the catalytic triad, consisting of serine, aspartine, and histine, at base 
pairs 115, 233, and 289, respectively, is necessary and sufficient for enzymatic 
activity (Calero et al., 2003; Schriner et al., 1996).  Two isoforms of human PPT1 
exist as monomers with molecular weights of either 37kDa or 35kDa, depending 
on glycosylation.  Functionally, PPT1 is a soluble lysosomal hydrolase that 
cleaves fatty acid side chains from lipid-modified proteins.  More specifically, 
PPT1 acts at the thioesterase cleavage site of membrane bound, palmitoylated 
proteins once targeted for degradation by the lysosome.  The optimum pH for 
PPT1 is quite broad and depends upon the substrate.  PPT1 is ubiquitously 
expressed throughout the CNS and viscera with the highest levels present in 
brain and testes.  Within the CNS, in situ hybridization experiments demonstrated 
that PPT1 expression is both developmentally and spatially regulated (Haltia et 
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al., 1973a).  High levels of enzyme are present in the cerebral cortex, CA1-CA3 
of the hippocampus, dentrate gyrus, and the hypothalamus.  Not surprisingly, 
these regions are the ones most severely affected by disease pathogenesis in 
INCL.  It is hypothesized that without the removal of fatty acid residues from 
palmitoylated proteins, small peptides become resistant to degradation and form 
large aggregates, a process similar to that found in Prion and Alzheimer’s 
Diseases.    
 Infantile neuronal ceroid lipofuscinosis is a debilitating, neurologic disease 
with a complex set of psychomotor dysfunctions due to widespread 
neurodegeneration.  Besides supportive care for patients, there is currently no 
therapy or cure for INCL.  Further work needs to be done to increase our 
understanding of disease progression in INCL in order to identify appropriate 
targets for therapeutic intervention.   
        
PPT1-deficient mouse 
Recently, a mouse model of INCL, the PPT1-deficient (PPT1-/-) mouse, 
was created by disrupting the PPT1 gene (Gupta et al., 2001).  A neomycin 
resistance cassette was introduced into exon 9 of the murine PPT1 gene 
introducing a premature stop codon in the PPT1 protein.  Immunoblot analysis 
coupled with enzymatic assays demonstrated the absence of both PPT1 protein 
and activity, respectively, making a functionally null mutant.  The PPT1 mutation 
was subsequently backcrossed onto the C57Bl/6 brain for 10 generations to 
develop a congenic model of INCL (Griffey et al., 2005).   
 9 
The phenotype of PPT1-/- mice mirrors the clinical course of INCL.  PPT1-
/- mice have a decreased life span compared to littermate controls where 50% of 
mice die by 7 months of age and 100% mice are dead by 10 months (Bible et al., 
2004; Griffey et al., 2004; Gupta et al., 2001).  Initial studies were performed to 
characterize the pathology and behavioral deficits at 7 months, an end stage of 
disease.  These studies demonstrated that the mice develop similar cognitive, 
motor, visual, and physiological deficits as patients with INCL.  Initial 
characterization studies described gait abnormalities in PPT1-/- mice at 4-5 mos. 
of age, which progressed to hind limb paralysis by 7 mos.  Seizure activity, 
largely myoclonic jerks, was observable at an end stage of disease.  EEGs of 7-
month PPT1-/- mice demonstrated an abnormal background (interictal) pattern of 
activity in addition to seizures (Griffey et al., 2006).  Electroretinograms (ERGs), 
a surrogate test for visual function, were abnormal as early as 2-3 mos. and 
worsened with age, demonstrating retinal deficits within the PPT1-/- mice.  Taken 
together, these data demonstrate that PPT1-/- mice show similar functional 
deficits as those observed in patients with INCL (Griffey et al., 2005). 
In addition to functional changes, the underlying pathology in the PPT1-/- 
mouse is similar to that seen in affected patients at a terminal stage of disease 
(Bible et al., 2004; Griffey et al., 2004; Gupta et al., 2001).  Overall, brains of 
PPT1-/- mice were significantly smaller than normal littermates.  Differential 
atrophy of various brain regions was observed with cortical areas most severely 
affected.  On a cellular level, widespread accumulation of autofluorescent 
material, specifically GRODs, was observed in PPT1-/- mice There is variation in 
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the temporal and spatial accumulation of GRODs, but by 7 months the entire 
brain was grossly affected (Galvin et al., 2008).  Widespread neurodegeneration 
was observed throughout the neuraxis.  In addition to changes observed in the 
neuronal population of PPT1-/- brains, abnormalities in the glia were also 
described.  Astrocyte reactivity and microglial activation was remarkable by 7 
months of age (Bible et al., 2004).   
Although INCL is considered primarily a neurodegenerative disease, the 
accumulation of GRODs is present in systemic tissues of the mouse, such as 
liver, kidney, and heart (Galvin et al., 2008).  Contrary to other LSDs, the clinical 
consequences of systemic accumulation of GRODs appear to be mild.  However, 
there are significant cardiac changes such as left ventricular hypertrophy and 
dilation of the ascending aorta.  These changes are consistent with the visceral 
symptoms observed in children with INCL.   
Taken together, the PPT1-/- mouse is an authentic murine model of INCL.  
Given the behavioral and physiological abnormalities observed, disease 
progression in the PPT1-/- mice mirrors that of the human course of disease.  
Similarly, the cellular pathology in the PPT1-/- mice at an end stage of disease is 
similar to the pathology described at autopsy in patients with INCL.  
 
Goals of thesis 
 Given the similarities between the murine model and human form of INCL, 
it is possible to further investigate the cellular pathology and functional deficits in 
the PPT1-/- mice to gain insights into the course of human disease.  The goals of 
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this thesis were to utilize the PPT1-/- mouse to obtain a better understanding of 
the disease progression associated with INCL and ultimately, develop novel 
therapies for the treatment of this disorder.   
Thus, the first aim of this thesis was to investigate the temporal and spatial 
progression of CNS disease in the congenic PPT1-/- mouse.  Based on the 
findings at autopsy in INCL patients as well as the preliminary data from the 
PPT1-/- mouse, we hypothesized that the progression of disease in the CNS 
involves both the neuronal and glial populations throughout the neuraxis.  We 
hypothesized that the cellular pathology would correlate both spatially and 
temporally with the functional changes associated with INCL.  Thus, 
characterization studies need to include not only the forebrain of PPT1-/- mice 
but also the hindbrain, where movement centers are located.  Furthermore, we 
sought to evaluate the time course of functional deficits in the PPT1-/- mouse, 
specifically in regards to physiology (seizure activity) and behavior (motor 
deficits). 
Based on the findings from our characterization studies (outlined in 
Chapter 2), we identified astrocyte activation, as defined by GFAP upregulation, 
as an early and prominent feature of this disease.  More specifically, our studies 
demonstrated that astrocyte activation is the first pathological change observed 
in the PPT1-/- brains, prior to any signs of neurodegeneration or functional 
deficits.  Therefore, the second aim of this thesis was to investigate the role of 
astrocyte activation in the disease progression of INCL.   
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Chapter Two 
 
 
 
Characterization of the forebrain & hindbrain 
pathology in the PPT1-/- mouse,  
a mouse model of INCL 
 
 
 
 
 
 
 
This chapter is adapted from the following manuscripts: 
Macauley SL, Wozniak D, Kielar C, Tang Y, Cooper JD, and Sands M.  
Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1 
deficient mouse. Exp. Neurol.  2009 May; 217(1):124-35. 
 
Kielar C., Maddox L, Bible E, Pontikis CC, Macauley SL, Griffey MA, 
Wong M, Sands MS, and Cooper JC. Neuron loss occurs in the thalamus before 
the cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol 
Dis. 2007 Jan; 25(1):150-62.  
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Introduction 
 
Infantile neuronal ceroid lipofuscinoses (INCLs), or Batten Disease, is an 
inherited neurodegenerative lysosomal storage disorder affecting the central 
nervous system (CNS) during infancy or childhood (Bennett and Hofmann, 1999; 
Goebel and Wisniewski, 2004; Hofmann and Peltonen, 2001).  INCL is the result 
of mutations in the CLN1 gene leading to a deficiency in the lysosomal enzyme, 
palmitoyl protein thioesterase 1 (PPT1; (Das et al., 1998; Hofmann et al., 2002; 
Mitchison et al., 1998; Mitchison et al., 2004; Vesa et al., 1995).  Hallmark 
pathological changes in the CNS include accumulation of autofluorescent 
material, neuronal loss, cortical thinning, and brain atrophy, which ultimately lead 
to cognitive deficits, motor dysfunction, seizure activity, and blindness (Hofmann 
et al., 1999; Hofmann and Peltonen, 2001; Santavuori et al., 1974; Vesa et al., 
1995) (Haltia et al., 1973a; Haltia et al., 1973b; Haltia et al., 1995; Hofmann and 
Peltonen, 2001; Vanhanen et al., 1997).  The neurodegeneration associated with 
INCL in humans is well documented; however, it remains unclear how the cellular 
pathology, in either neurons or glia, within the CNS contributes to physiological 
deficits and behavioral impairment.  Further investigation into the specific cellular 
pathology of neurons and astrocytes is necessary to better understand INCL and 
develop effective therapies for this disorder. 
 
Initial characterization studies 
 A mouse model of PPT1-deficiency was created by a targeted disruption 
in the CLN1 gene (Gupta et al., 2001).  The initial characterization was 
 14 
performed at an end stage of disease and demonstrated that the PPT1-deficient 
mouse (PPT1-/-) shares many of the histological and clinical features of INCL 
(Bible et al., 2004; Griffey et al., 2004; Griffey et al., 2005; Kielar et al., 2007).  
Although mice develop normally from birth, premature death occurs by 8.5-9 
months. Phenotypically, these mice suffer from blindness (Griffey et al., 2005), 
seizures (Griffey et al., 2006; Kielar et al., 2007), cognitive deficits, and motor 
dysfunction (Griffey et al., 2004; Griffey et al., 2006) at the end stage of disease.  
These behavioral deficits are mirrored in children affected by INCL.    
Upon gross examination of the PPT1-/- brains, Bible et al. (2004) 
described an overall brain atrophy at 7 mos. of age.  The affected mice have a 
20-25% decrease in brain weight (Bible et al., 2004; Griffey et al., 2004) 
compared to wildtype (WT) controls.   Although an overall decrease in brain 
mass occurs in the PPT1-/- mouse, the extent to which certain areas are affected 
differs from region to region.  For example, a significant decrease in brain mass 
was present in the cortex, thalamus, striatum, and hippocampus of PPT1-/- mice; 
areas similarly affected in patients with INCL.  The greatest volumetric change 
was observed in the thalamus (i.e. 46% decrease), while the cortex and striatum 
suffered a 35% and 30% reduction, respectively.  Furthermore, decreases in 
cortical thickness varied based on the region of cortex investigated.  Although 
decreases in cortical thickness were apparent in numerous cortical areas (i.e. 
motor, visual, somatosensory, and entorhinal cortex), the visual cortex and 
somatosensory cortex were the most severely affected.   
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Similar to patients with INCL, the CNS atrophy described is the result of 
neuronal loss throughout the neuraxis of PPT1-/- brains.  There is a significant 
decrease in neuron number in both the cortex and hippocampus, most notably 
within the interneuron population.  Concurrent with the neuronal loss, there is an 
increase in autofluorescent accumulation in the cortex, striatum, and cerebellum 
of PPT1-/- brains.  Although autofluorescent accumulation is a hallmark of INCL, 
there is no causal link between neuronal hypertrophy due to autofluorescent 
accumulation and neuronal death in the PPT1-/- mouse.    
Concurrent with the characterization of the neuronal pathology, initial 
studies investigated glial reactivity as well.  In a 7 mo. PPT1-/- mouse, there is a 
significant increase in both astrocyte activation (i.e. GFAP upregulation) and 
microglial reactivity (i.e. F4/80 upregulation) in the cortex, hippocampus, and 
striatum.  This demonstrates that neuroinflammation plays a role in the 
pathogenesis of INCL, a phenomenon similarly described in human patients. 
Initial characterization studies demonstrated that the phenotype of the 
PPT1-/- mouse mirrored the behavioral deficits and cellular pathology described 
in INCL patients at the end stage of disease.  Based on these findings, we 
believe the PPT1-/- mouse is a valuable tool for investigating the disease 
pathogenesis of INCL.  Although the pathology of INCL patients at autopsy is 
well described, it remains unclear how a genetic mutation, such as a CLN1 
mutation, can evolve into such a debilitating, neurologic disease.  Thus, studies 
investigating the temporal-spatial progression of cellular pathology and 
behavioral deficits should be employed to gain a better understanding of INCL.  
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Aims of temporo-spatial characterization studies 
The research aims seeking to further characterize the PPT1-/- mice were 
two fold.  First, our primary goal in these studies was to investigate the disease 
progression in the cerebellum.  Although profound motor deficits and cerebellar 
pathology is described in patients with INCL, the initial characterization studies in 
the PPT1-/- mouse did little to investigate the underlying pathology in the 
hindbrain.  Apart from a brief description of gait abnormalities and qualitative 
reports of Purkinje cell loss in the PPT1-/- mouse, no additional investigation of 
cerebellar pathology or motor deficits was performed.  In addition to the autopsy 
information from INCL patients, gene therapy studies in PPT1-/- mice 
demonstrated that the most efficacious gene therapy strategy for the treatment of 
INCL occurred when viral vectors were targeted to the cerebellum in combination 
with the forebrain.  Again, these data suggests the disease is not restricted to the 
forebrain and further investigation of cerebellar pathology is warranted.  Thus, 
our primary goal was to perform a time course investigating the cellular pathology 
and functional deficits associated with the cerebellar disease. In this study, we 
determined the temporal changes in cellular pathology in both neurons and glia.  
Concurrently, we quantified the progression of motor dysfunction.  Taken 
together, these studies provide insight into the disease pathogenesis of INCL 
cerebellum and its relationship to motor function (Macauley et al., 2009). 
The second aim of our characterization studies focused on expanding the 
initial descriptions of pathology and behavioral deficits localized to the forebrain.  
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This study was carried out in collaboration with Catherine Kielar and other 
members of Dr. Jonathan Cooper’s laboratory at Kings College, London (Kielar 
et al., 2007).  Although the descriptions of forebrain pathology at an end stage of 
disease in the PPT1-/- mice were thorough, a temporal investigation of pathology 
and functional deficits would provide insight into the evolution of disease in INCL.  
A summary of results from this study is also included in Chapter 2.   
  
Methods 
PPT1-/- Mice 
PPT1-/- mice were created as previously described on a mixed 
background (Gupta et al., 2001).  Subsequently, the mice were bred to C57Bl/6 
mice for 10 generations to produce a congenic strain (Griffey et al., 2004).  
Wildtype (+/+) or PPT1- deficient (-/-) mice were generated by either 
heterozygous (+/-) or homozygous (-/-; +/+) matings at Washington University 
School of Medicine by M.S.S.  Mouse genotype was determined by a PCR-based 
assay.  Both male and female PPT1-/- mice and normal littermates (+/+) were 
used in this study.  Animals were housed under a 12:12 hour light:dark cycle and 
were provided food and water ad libitum.  All procedures were carried out under 
an approved IACUC protocol from Washington University School of Medicine.  
Cerebellar Weights 
 Seven month PPT1-/- (n=6) and wildtype littermates (n=5) were sacrificed 
via CO2 asphyxiation and the brains harvested by a researcher blinded to 
genotype and age.  A sharp knife was inserted coronally into the transverse sinus 
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to separate the cerebellum from the forebrain.  Similarly, a coronal cut was made 
immediately posterior to the cerebellum, separating the cerebellum from the 
medulla and spinal cord.  Care was taken to ensure that the cut was flush with 
the back of the cerebellum.  Each cerebellum was weighed using an analytical 
balance and group differences in weights were analyzed using an independent 
groups t test. 
Quantification of Purkinje cells 
Congenic PPT1-/- mice (n=3-6 per time point) and wildtype littermates 
(n=3-4 per time point) at 1, 3, 5, 6, and 7 mo. of age were used in this study.  
Briefly, mice were sacrificed via CO2 asphyxiation, brains removed and post-fixed 
for 48 hours in 4% paraformaldehyde in phosphate buffered saline (PBS).  
Cerebella were separated from the forebrain and bisected in the sagittal plane 
about 1 mm off midline.  The larger piece was embedded sagittally in paraffin 
and sectioned at 5µm through the midline.  Sections were stained with 
hematoxylin & eosin (H&E).  Counts of surviving Purkinje cells were made from 
midsagittal sections through the vermis for each lobe.  Purkinje cells were 
counted if they possessed a well-defined cytoplasm and nucleus with the 
presence of a distinct nucleolus.  Purkinje cells undergoing degeneration 
possessed a shrunken, pyknotic appearance with irregular margins and were not 
counted.  The number of healthy Purkinje cells was recorded for each lobule (I 
through X) of the PPT1-/- and wild type cerebellum.  For statistical analysis, data 
from wild type mice at the various ages counted (1-7 mos.) were collapsed and 
treated as a single wild type group.  Previous work as (Macauley et al., 2008b) 
 19 
well as data from this study demonstrated that Purkinje cell counts do not differ 
significantly over this age range.  The Purkinje cell count data were analyzed by 
a repeated measures ANOVA model containing one between-subjects variable 
(groups) and one within-subjects variable (lobes), and subsequent pairwise 
comparisons.  Bonferroni correction was used to maintain alpha levels at 0.05 
when multiple comparisons were conducted.  
Quantification of the Granular cell layer 
 To examine granule cell survival within lobule IV/V of the cerebellum, we 
used StereoInvestigator software (MicroBrightField Bioscience, Williston, VT) to 
obtain unbiased optical fractionator estimates of granule cell number from H&E 
stained sections. Cells were sampled using a series of counting frames 
distributed over a grid superimposed onto the section, with a random starting 
section chosen, followed by every fourth section thereafter.  The sizes of the 
‘sampling grid’ and of the ‘dissector frame’ used in this study were 250x160µm2 
and 20x20µm2 respectively. Only clearly identifiable cells that fell within the 
dissector frame were counted, using a x100 oil objective.  
The statistical significance of differences between genotypes of all 
quantitative data was assessed using a one-way ANOVA (SPSS 11.5 software, 
SPSS Inc, Chicago, IL), with statistical significance considered at p< 0.05. The 
mean coefficient of error (CE) for all individual optical fractionator and Cavalieri 
estimates was calculated according to the method of Gundersen and Jensen 
(1987) and was less than 0.08 in all analyses. 
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Immunohistochemistry for neuronal, astrocytic, & microglial markers 
PPT1-deficient mice and wildtype littermates were sacrificed via CO2 
aphyxiation for immunohistochemistry at 1, 3, 5, 6 and 7 months of age. The 
brains were removed, fixed in 4% paraformaldehyde in phosphate buffer, and 
cryoprotected with 30% sucrose in tris-buffered saline (TBS).  Brains were 
sectioned in the sagittal plane through the vermis (20µm) using a freezing 
cryostat.  Adjacent, free floating sections were stained with the following 
antibodies: rabbit anti-glial fibrilllary associated protein (GFAP; 1:200 
ImmunoStar, Inc.), rabbit anti-S100ß (1:200; Abcam), rat anti-F4/80 (1:100; 
Serotec), mouse anti-calbindin (1:1000; Sigma), guinea pig anti-GLAST (1:2000; 
Chemicon) rabbit anti-GLT1 (1:100; Santa Cruz), and rabbit anti-glutamine 
synthetase (GS; 1:200 Santa Cruz).  Briefly, sections were washed in tris-
buffered saline (TBS), incubated in 1% H2O2 (Sigma) to quench endogenous 
peroxidase activity, and rinsed thoroughly in TBS.  The tissue was blocked for 1 
hour in 10% normal goat serum (NGS; Sigma), 0.25% Triton X-100 in TBS.  
Sections were incubated overnight at 4˚C in primary antibodies in 5% NGS, 0.2% 
Triton X-100 in TBS.  The following day the sections were rinsed in TBS and 
incubated in secondary antibodies (1:200; Vector Labs) in 10% NGS, 0.1% Triton 
X-100 in TBS for 75 minutes.  The tissue was rinsed in TBS and then incubated 
in a peroxidase conjugated avidin-biotin complex (1:200; Vectastain Elite ABC kit 
from Vector Labs) for 1 hour at RT.  Antibody immunoreactivity was visualized 
with 3’-3’ diaminobenzidine and H2O2 (DAB kit; Vector Labs) in TBS.  Sections 
were dehydrated and coverslipped.  
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DeOlmos Cupric Silver Staining 
Six, 7 and 8 mo. old PPT1-/- mice (n=2 per time point) and wildtype 
littermates (n=1-2 per time point) were deeply anesthetized with euthasol and 
transcardially perfused with 4% paraformaldehyde in sodium cacodylate buffer. 
The brains were removed and post-fixed for 48 hours.  Each brain was 
embedded in a gelatin-based matrix (Switzer, 2000) and serial coronal sections 
(35 µm) were cut on a freezing microtome by Neuroscience Associates 
(Knoxville, TN).  Neuronal degeneration was visualized by staining with a 
modified cupric silver method of DeOlmos  (DeOlmos & Ingram, 1972; Switzer, 
2000).  A matrix of PPT1-/- and WT brains at identical levels in the coronal plane 
were stained simultaneously.  Every sixth section (210 µm interval) was stained 
with the silver method and adjacent sections stained with H&E. 
Luxol Fast Blue & PAS Stain 
 Seven-month-old PPT1-/- and wildtype littermates were sacrificed and 
sectioned at 20µm as described above.  Every 12th section throughout the vermis 
was stained with luxol fast blue and Periodic-acid Schiff stain.   
TUNEL Staining 
TUNEL staining was performed on sagittal sections throughout the 
cerebellum of PPT1-/- mice and wildtype littermates at 1, 3, 5, 6, and 7 months of 
age using the Apoptag Apoptosis Detection Kit (Milipore Corp) per the 
manufacturers instructions.  Briefly, sections were warmed to room temperature 
(RT) and treated with proteinase K (20µg/ml) for 15 minutes at RT.  Immediately 
following, endogenous peroxide was quenched with 1% hydrogen peroxide in 
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methanol.  After sections were incubated in equilibration buffer for 1 minute, 
working strength terminal deoxynucleotidyl transferase (TdT) enzyme was added 
to the tissue and incubated in a humidified chamber at 37˚C.  After a 60-minute 
incubation, the reaction was stopped by the addition of working strength 
stop/wash buffer for 10 minutes.  An anti-digoxigenin conjugate was placed on 
each specimen for 30 minutes and the reaction visualized with DAB substate.  
The tissue was counterstained with nuclear fast red. 
Rotarod Testing 
Congenic PPT1-/- mice (n=11-14 mice per group) and wildtype littermates 
(n=11-14 mice per group) were tested on the constant speed rotarod (2.5 rpms) 
at 1, 3, 5, 6, and 7 months of age.  Latency to fall served as the dependent 
variable and trials lasted a maximum of 60 s.  At each age, mice received three 
test sessions where each session included a pretest trial on a stationary rod, 
followed by two test trials on the constant speed rotarod.  To combat the effects 
of training, only the last test session was used in computing statistical differences 
with the previous two trials treated as training.  A repeated measures ANOVA, 
including one between-subjects variable (genotype) and one within-subjects 
variable (age), was the main analysis conducted on monthly performance.  
Additional analyses (independent groups and paired t test, respectively) were 
performed on 1- and 7- month time points due to smaller sample sizes at these 
ages. 
Seizure Activity 
 C57Bl/6 controls (n = 4) and PPT1−/− mice at 6 (n = 4), 6.5 (n = 6), 7 (n = 
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6) and 7.5 (n = 7) months of age were monitored for seizure activity and interictal 
EEG activity using simultaneous video and EEG recordings (Griffey et al., 2006).  
Briefly, each mouse was implanted with four epidural screw electrodes two days 
prior to monitoring.  Each monitoring session consisted of a continuous 48-hour 
period.  During each session, mouse behavior was captured via video monitoring 
while EEGs were recorded using a computer interface and AxoScope software 
(Molecular Devices, Sunnyvale, CA).  Seizures were identified using both 
behavioral and EEG recordings. The number of animals with seizures, the 
number of seizures per animal, and seizure duration will be counted for each 
animal during each monitoring period. Statistical analysis was performed using 
Kruskal–Wallis non-parametric ANOVA. Additionally, the background EEG was 
scored by a board certified neurologist blinded to genotype. For analysis of the 
interictal EEG back- ground, one-minute segments obtained from every 4 h of the 
48 h EEG record were randomly selected and graded with a previously described 
scale (Griffey et al., 2006) comprising: Grade 1 (normal)—normal background 
theta rhythm with no spikes, Grade 2 (mildly abnormal)—mostly normal 
background with some epileptiform spikes, Grade 3 (moderately abnormal)—
mostly abnormal background with frequent epileptiform spikes, Grade 4 (severely 
abnormal)—burst-suppression pattern. A mean interictal EEG grade was 
calculated for each genotype, and statistical comparisons were made using 
ANOVA with Tukey–Kramer multiple comparison post hoc test.  
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Results from Cerebellar Study 
Cerebellar Weights 
Upon gross inspection at 7 mo. of age, the PPT1-/- cerebella appeared 
smaller than aged matched wildtype littermates (Figure 1A).   The mean weight 
of PPT1-/- cerebella was 0.076g (SEM±0.0054) compared to 0.112g 
(SEM±0.0022) for normal mice.  At an end stage of disease (7 mo.), analysis of 
cerebellar weights (Figure 1B) demonstrated a significant loss of mass in the 
PPT1-/- mice, [t(9) = 5.77, p < 0.0005]. 
deOlmos Cupric Silver Staining 
 Silver staining was performed on 6, 7, and 8 mo. PPT1-/- mice and 
wildtype controls (Figure 2).  Representative images of the anterior lobes of the 
cerebellum in the coronal plane are shown in Figure 2.  As PPT1-/- mice aged,  
Figure 1. An overall atrophy is observed in the PPT1-/- cerebellum at 7 mo. of age. 
(A) Representative images of PPT1-/- and wildtype cerebella.  Notice the size 
differential between the mutant and wildtype control.  (B) Quantification of the cerebellar 
weights in PPT1-/- (n=5) and wildtype mice (n=5) revealed a statistically significant 
decrease in cerebellar mass in PPT1-/- mice compared to wildtypes (p<0.002). 
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Figure 2. DeOlmos cupric silver degeneration staining in PPT1-/- mice. (A-D) 
Representative coronal images of silver staining in the anterior cerebellum of 7 mo. WT (A), 6 
mo. PPT1-/- (B), 7 mo. PPT1-/- (C), and 8 mo. PPT1-/- mice (D).  Notice the overall increase in 
silver staining as the PPT1-/- mice age, most notably within the cerebellar white matter. (E) 
Higher magnification image of the 7 mo. PPT1-/- cerebellum.  In addition to the cerebellar white 
matter, silver stained parasagittal bands, or blackened stripes, are visualized in the molecular 
layer in the cerebellar cortex.  Locator boxes identify the areas magnified in subsequent panels.  
(F & G) High magnification of parasagittal banding found in an individual folia of PPT1-/- mice at 
7 mo.  The banding seen in the molecular layer is staining of the dendritic arbors of diseased 
Purkinje cells.  Blackened debris litters the Purkinje cell layer, most likely due to dying Purkinje 
cells.  (H) High magnification of a degenerating Purkinje cell, with a blackened soma and 
dendritic arbor.  (I) High magnification image of the cerebellar white matter tracts contains 
degenerating efferent and afferent projections to the cerebellar cortex.  Degenerating axons 
represent the sole output of the PPT1-/- cerebellum. 
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there was a progressive increase in neurodegeneration as visualized by silver 
staining (Figure 2B, C, D; respectively) when compared to normal (Figure 2A).  
When the CNS undergoes neurodegeneration, neurons bind silver causing 
individual cells and processes to appear ‘blackened’ with this staining method.  
Thus, at low magnification, diffuse silver staining was appreciable in the 
cerebellum at 6 mo. of age, most notably in the white matter tracts throughout the 
vermis and lateral hemispheres.  As the mice aged, the intensity and distribution 
of staining increased to include ‘patches’ throughout the Purkinje cell and 
molecular cell layers.  At 8 mo. of age, widespread neurodegeneration was 
evident in the anterior lobes of the cerebellum, although the staining was of equal 
or lower intensity. 
Higher magnification images of a 7 mo. old PPT1-/- brain show 
parasagittal bands of degenerating Purkinje cells in the cerebellar cortex of the 
vermis and lateral hemispheres (Figure 2E, F).  The molecular layer was littered 
with fragmented dendritic arbors associated with dying Purkinje cell neurons 
(Figure 2H).  In addition to their dendritic arbors, the cerebellar white matter 
tracts, composed of afferant and efferent fibers, displayed an intense silver 
staining (Figure 2G, I). 
Purkinje cell degeneration 
The Purkinje cell layer in wildtype mice consists of a one-cell-thick 
monolayer of contiguous Purkinje neurons nestled between the molecular and 
granular cell layers of the cerebellum (Figure 3B).  In contrast, there was a clear 
disruption in the Purkinje cell layer in PPT1-/- mice (Figure 3B), immediately  
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Figure 3.  Purkinje cell loss in the PPT1-/- cerebellum.  (A)  Schematic representation of 
lobes I-X of the cerebellar vermis.  (B) H&E stained cerebella from PPT1-/- and wildtype mice.  
Black arrows indicate a contiguous Purkinje cell monolayer present in WT cerebellum.  In the 
PPT1-/- cerebellum, white arrows indicate patches of missing Purkinje neurons.  (C) Graphical 
representation of Purkinje cell survival (total cell number±SEM) in PPT1-/- cerebella at 1, 3, 5, 
6, and 7 mo. of age.  (D) Purkinje cell survival by lobe (as a percent of normal) in 1, 3, 5, 6, and 
7 mo. PPT1-/- mice. (E) Calbindin staining in the PPT1-/- cerebellum.  At low magnification, 
there were comparable levels of staining in a 1 mo. WT and PPT1-/- cerebellum.  By 3 mo. of 
age, loss of calbindin staining appeared in patches throughout the anterior cerebellum (arrows).  
By 7 mo. of age, nearly half of the cerebellum lacked calbindin immunoreactivity.  At high 
magnification, the molecular and Purkinje cell layers of 1 mo. WT and PPT1-/- cerebella 
appeared normal with darkly stained Purkinje cell bodies and dendritic arbors.  As the mice 
age, there was a decrease in the intensity of calbindin staining, a denudation of the Purkinje 
cell layer and pruning of the dendritic arbors.  The white arrow identifies a swollen dendrite.  
Comparable levels of calbindin staining were observed in 1, 3, 5, 6, and 7 mo. wildtype mice.  
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illustrating cell loss at 7 mo. of age throughout both the anterior-posterior as well 
as the medial-lateral axis of the cerebellum.  Additionally, remaining Purkinje 
cells appeared unhealthy, presenting with a shrunken cytoplasm and a foamy 
appearance characteristic of lysosomal distension.  To further investigate this 
apparent neuronal loss, Purkinje cell counts were performed throughout the 
vermis on each lobe (I-X; Figure 3A) from wildtype and PPT1-/- brains at 1, 3, 5, 
6, and 7 mo. of age.  At 5 mo. of age, there was a trend towards a decrease in 
total Purkinje cell number (13% decrease in total number; p=0.08).  By 6 months 
of age, there was a statistically significant decrease in total Purkinje cell number 
(p=0.005) and culminated in a 50% reduction in total number at 7 mo. of age 
(p<0.0005; Figure 3C).  Regionally, loss of Purkinje cells began at 3 mo. of age in 
the most anterior lobes.  Although there was only a 3% decrease in total Purkinje 
cell number at 3 mo., there was a 23% decrease in cell number in lobe I/II 
compared to normal littermates (Figure 3D).  By 5 mo., Purkinje cell death 
increased in posterior lobes.  At 6 mo. of age, pairwise comparisons conducted 
for each lobe showed significant cell loss (beyond Bonferroni correction) in lobes 
I/II (p=0.039), IV/V (p=0.019), VI (p=0.001), VII (p=0.018), and VIII (p=0.003), 
with lobes IX and X spared.  All lobes suffer a ≥50% reduction in Purkinje cell 
number by 7 mo. of age (p≤0.001).  No change in Purkinje cell number is 
observed in PPT1-/- mice at 1 mo. of age. 
In addition to quantifying neuronal loss, we investigated the morphology of 
the remaining neurons as an indicator of their general health.  To examine any 
gross changes seen in Purkinje cell morphology, a time course of PPT1-/- and 
 29 
wildtype control brains were stained with an antibody against the calcium binding 
protein, calbindin.  At low magnification, calbindin-stained Purkinje cells from lobe 
IV/V appeared indistinguishable in PPT1-/- brains compared to age-matched 
normal littermates at 1 mo. of age (Figure 3E).  A contiguous layer of calbindin-
positive cell bodies occupied the Purkinje cell layer, while the molecular layer 
was filled with a network of darkly stained dendritic arbors (black arrows).  In 
addition, axonal projections from the Purkinje cell layer were observed 
transversing the granular cell layer.  At 3 mo., gaps in calbindin-positive staining 
were appreciable at low magnification in the anterior lobes (I-V) of the PPT1-/- 
cerebellum, consistent with our counts of Purkinje cell number.  At higher 
magnification, there was a decrease in the density of staining within the 
molecular layer demonstrating a pruning of dendritic arbors of the Purkinje cell 
neurons.  By 5 mo. of age, numerous disruptions in calbindin staining throughout 
the anterior-posterior axis of the cerebellum were seen at low magnification.  At 
higher magnification, the molecular layer appeared disorganized while the axonal 
projections through the granular cell layer looked fractured and swollen.  By 7 
mo. of age, Purkinje cell loss was widespread, with large gaps in staining 
throughout the cerebellar vermis.  In addition, frank cell loss was appreciable in 
the lateral hemispheres of the cerebellum similar to the vermis (data not shown).  
On closer inspection, the soma of Purkinje neurons often displayed irregular 
margins with little to no dendritic arborization observed.  Where arbors remained, 
swollen dendrites in Purkinje cells were observed (Figure 3E; white arrow). In 
addition to the profound Purkinje cell death that occurs in the PPT1-/- 
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cerebellum, the remaining Purkinje cells, even at an early time point, appeared 
unhealthy.   
Apoptosis and Assessment of Granular Cell Loss  
Although widespread Purkinje cell loss occurs at a variety of ages, the 
only TUNEL-positive profiles were observed within the granular cell layer on 
PPT1-/- mice at 7 mo. of age (Figure 4A). To investigate granule cell loss, cell 
counts in the granular cell layer were performed throughout the vermis of lobe 
IV/V in wildtype and PPT1-/- brains at 1, 5 and 7 mo. (Figure 4).  At 7 mo. of age, 
Figure 4.  Cell loss in the granular cell layer.  (A) TUNEL-positive cells were found in 
the granular cell layer (GCL) of the 7 mo. PPT1-/- cerebellum.  Nuclear fast red staining 
identified cells within the granular cell layer at low magnification.  At high magnification, 
numerous darkly stained, TUNEL + profiles were observed throughout the GCL (dark 
staining; arrows).  (B) Quantification of the granular cell number demonstrated a 
statistically significant (p<0.05; asterisk) cell loss at 7 mo. of age, with no changes in total 
cell number evident before this age.  No TUNEL positive cells were observed in 1, 3, 5, 6, 
and 7 mo. wildtype mice.    
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there was a statistically significant [F(1,4) = 44.37, p = 0.003] decrease in total 
number of cells within the granular cell layer in PPT1-/- mice.  Total cell number 
was estimated to be 3.46x105 within lobe IV/V of mutant mice compared to 
4.47x105 in age-matched wildtype controls (Figure 4B).  This represents a 23% 
percent cell loss in the granular cell layer at 7 mo. of age.  At earlier time points 
investigated, there was no decrease in the number of granule cells in lobe IV/V, 
suggesting this loss of neurons is a later stage phenomenon.  
Astrocyte activation 
 Astrocyte activation, visualized by glial fibrillary associated protein (GFAP) 
upregulation, began at an early age (Figure 5A).  At 1 mo. of age, there was a 
slight increase in GFAP staining in PPT1-/- mice compared to wildtype controls.  
By 3 mo., the Bergmann glia (Golgi epithelial cells) displayed a clear increase in 
GFAP immunoreactivity both at the cell body and within their processes.  At low 
magnification, this staining appeared ‘patchy’ throughout the A-P axis of the 
cerebellum.  Astrocyte activation continued to increase at 5 mo. of age, and by 7 
mo., the entire molecular layer throughout the vermis of lobes I-X was strongly 
immunoreactive for GFAP.  At high magnification, there was an increase in 
number of GFAP-stained Bergmann glial processes in the molecular layer as well 
as an apparent hypertrophy of individual glial processes.  
Astrocyte Dysfunction 
 In an effort to quantify astrocyte cell number, S100ß staining, a calcium 
binding protein largely localized to astrocytes, was performed on cerebella from 
PPT1-/- and wildtype littermates (Figure 5B).  As the PPT1-/- mice aged, there  
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Figure 5.  Astrocyte changes in the PPT1-/- cerebellum.  (A) GFAP staining was 
performed on 1, 3, 5, and 7 mo. PPT1-/- cerebella.  Astrocyte activation was found in PPT1-/- 
mice as early as 1 mo. of age, with a diffuse increase in GFAP immunoreactivity.  By 3 mo. of 
age, there was a hypertrophy of astrocytic processes and patches of GFAP upregulation 
through the PPT1-/- cerebellum (black arrows).  This phenomenon continues as the mice age.  
Comparable levels of GFAP staining were observed in 1, 3, 5, 6, and 7 mo. wildtype mice.  
(B) Astrocyte dysfunction in the PPT-/- mouse.  S100ß staining was performed on 1, 3, 5, 6, 
and 7 mo. PPT1-/- cerebella.  Compared to WT, there was an overall decrease in S100ß by 5 
mo. of age (black arrows).  Most notably, there was a progressive loss of immunoreactivity in 
the Bergmann glia and astrocytes of the granular cell layer.   
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was an overall decrease in S100ß staining throughout the cerebellum.  In the 
wild type control, S100ß-positive cell bodies were mostly localized within the 
granular and Purkinje cell layers.  Diffuse staining of Bergman glial fibers was 
also apparent within the molecular layer.  By 3 mo. of age, the PPT1-/- cerebella 
showed a decrease in the intensity of S100ß immunoreactive cell bodies, most 
notably within the granular cell layer.  As the mice age, the S100ß -positive 
Bergman glia, with their cell bodies intermixed with Purkinje neurons in the 
Purkinje cell layer, demonstrated a loss of immunoreactivity.  In addition, there 
was a diffuse loss of S100ß staining within all layers of the 7 mo. PPT1-/- 
cerebellum. S100ß -positive cell bodies were absent from both the Purkinje cell 
and granular cell layers.  
Glutamine Synthetase (GS), GLAST, & GLT-1 Immunohistochemistry 
 To further investigate whether the loss of S100ß immunoreactivity was 
due to changes in protein expression or due to a loss of astrocytes, we used a 
second astrocyte marker, glutamine synthetase (GS), to stain 7 mo. old wildtype 
and PPT1-/- mice (Figure 6).  There was a decrease in GS staining in the 7 mo. 
PPT-/- cerebellum compared to normal controls.  Although there was an 
appreciable loss of neuropil in the PPT1-/- cerebellum at 7 mo., the remaining 
cells in the granular cell layer stained for GS.  Qualitatively, the number of GS-
positive cell bodies in the molecular layer seemed less than the wild type control.  
Importantly, there was a considerable decrease in the number of GS-
immunoreactive cell bodies in the Purkinje cell layer, suggestive of a loss of 
Bergman glia at 7 mo. of age. 
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Figure 6. Glutamine synthetase (GS), GLAST, and GLT-1 staining in 7 mos. 
PPT1-/- and WT mice.  An apparent loss of GS staining was observed in the 
cerebellar cortex of 7 mos. PPT1-/- mice.  Most notably, there was a loss of staining 
within the cell bodies of the Bergmann glia (black arrows).  GLAST staining in PPT1-/- 
mice demonstrated a diffuse, overall reduction in immunoreactivity compared to WT.  
A decrease in GLAST expression in the Bergmann glia (arrows) and the molecular 
layer was also apparent.  In contrast, GLT-1 staining was comparable in WT and 
PPT1-/- mice.  A notable exception is the intensity of staining in the Purkinje cell 
layer, which was markedly reduced in the PPT1-/- mice. 
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 Given the number of changes observed in PPT1-/- astrocytes, we 
performed immunohistochemistry staining for several astrocyte specific 
glutamate transporters, GLAST and GLT-1, in PPT1-/- and wild type mice (Figure 
6).  At low magnification, the wild type-Bergman glia were largely immunoreactive 
for GLAST, with punctate staining present in the Purkinje cell and molecular 
layers.  In contrast, the PPT1-/- cerebellum at 7 mo. of age suffered an overall 
decrease in GLAST immunoreactivity.  At higher magnification, this change in 
protein expression was most notable in the Bergmann glial processes in the 
molecular layer, with a near complete loss of staining at 7 mo. of age.   
 Although GLAST expression was altered in the PPT1-/- mice, GLT-1 
staining in the cerebellar folia seemed relatively unchanged when compared to 
wildtype littermates.  The major change in GLT-1 staining in mutant mice 
coincided with a loss of Purkinje cells at 7 mo. of age.  The normal pattern of 
GLT-1 staining circumscribes the Purkinje cell bodies and in their absence in 
mutant mice, this staining is lost.  Otherwise, comparable patterns and levels of 
GLT-1 staining were apparent in both PPT1-/- and wildtype cerebella in the 
granular cell and molecular layers.      
Microglial Reactivity 
 PPT1-/- and wildtype brains were stained for F4/80, a marker for microglia 
and macrophages (Figure 7).  Prior to 5 mo. of age, there was no detectable 
F4/80 staining within the brains PPT1-/- mice or wildtype littermates.  At 5 mo. of 
age, an increase in F4/80 staining was evident in the PPT1-/- cerebellum.  The 
F4/80-positive cells, mostly comprised of small-ramified cells, were evenly 
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dispersed throughout the molecular, Purkinje cell, and granular cell layers.  As 
the mice age, there was a progressive increase in the number of positively 
stained cells in the PPT1-/- cerebellum.  In addition, the morphology of the 
positive cells changed from small-ramified cells (A) to large, round cells with 
brain macrophage-like morphology (B) as the mice age.  
Luxol Fast Blue and Periodic acid Schiff staining 
 Luxol Fast Blue (LFB) and Periodic acid Schiff (PAS) staining were 
performed on 7 mo. old PPT1-/- mice and normal littermates (Figure 8).  Upon 
gross examination, the white matter tracts, as visualized by LFB, appeared 
thinner in PPT1-/- mice (arrows) compared to normal littermates.  At higher 
magnification, LFB staining revealed an array of densely stained myelinated 
Figure 7.  F4/80 staining, a monocyte marker, in PPT1-/- and wildtype mice.  PPT1-/- mice 
showed an increase in the number of monocytes starting at 5 mos. of age.  As the mice age, 
there was an increase in monocytes at 6 and 7 mos. (black arrows).  In addition, there was a 
change in the morphology of the F4/80 positive cells from small, ramified cells with a microglial 
morphology (A) to larger rounded brain macrophage-like cells (B). Comparable levels of F4/80 
staining were observed in 1, 3, 5, 6, and 7 mo. wildtype mice. 
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fibers traversing through the white matter in the wildtype mouse.  In contrast, the 
PPT1-/- cerebellar white matter appeared disorganized, less intensely stained 
and littered with ‘holes’.  Furthermore, the number of densely stained cell bodies 
in the white matter was decreased and the morphology of the remaining cell 
bodies appeared shrunken and irregular in PPT1-/- mice.  These densely stained 
cells are glia, most likely oligodendrocytes, given their localization and 
organization in the cerebellar white matter. 
 PAS staining, a marker of glycogen storage was performed on 7 mo. 
PPT1-/- mice.  There was a noticeable increase in the intensity of PAS staining in 
the vasculature of the white matter tracts (black arrows).  In addition, PAS-
Figure 8.  Luxol Fast Blue (LFB) and Periodic acid-Schiff (PAS) staining in 
the PPT1-/- cerebellum.  Staining for the myelin marker, luxol fast blue, was 
markedly decreased in PPT1-/- mice at 7 mo.  At low magnification, there was a 
thinning of the cerebellar white matter tracts in the PPT1-/- mice compared to 
WT.  At high magnification, the intensity of staining and organization of the 
white matter was disrupted in the PPT1-/- cerebellum.  PAS staining (red) 
demonstrated glycogen inclusions in the molecular layer and Purkinje cell layers 
of PPT1-/- mice.  In addition, the vasculature in the white matter tracts was PAS 
positive (arrows). 
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positive cells were present in the molecular layer and Purkinje cell layers of the 
PPT1-/- cerebellum, but only at a late stage of disease (5-7 mo.).     
Rotarod Testing 
PPT1-/- mice and normal littermates were tested on the rotorod at 1, 3, 5, 
6 and 7 mo. of age and latency to fall was recorded (Figure 9).  At 1 mo. of age, 
the performance of PPT1-/- mice and normal littermates was indistinguishable on 
the rotorod (54.9s v. 54.7s; respectively).  The latency to fall began to decrease 
in PPT1-/- mice compared to WT mice at 3 mo. of age (55.6s v. 48.9s; 
respectively), although this was not a significant change.  By 5 mo. of age, the 
ability of the PPT1-/- mice to stay on the rotorad was significantly impaired 
(39.5s; p≤0.0005), while wildtype littermates continued to perform near criterion 
Figure 9.  Constant speed rotarod testing in the PPT1-/- mice.  PPT1-/- 
mice display significant motor deficits (p<.0.0005) on the rotarod test 
beginning at 5 mo. of age, and continuing through 6 (p<.0.0005) and 7 
(p≤0.001) months of age.  The asterisk denotes statistical significance.  WT 
mice performed at criterion for the entire task. 
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(55.9s).  The performance of PPT1-/- mice continued to decrease at 6 mo. 
(27.1s; p<0.0005) and reached a nadir at 7 mo. of age (1.8s; p≤0.001).  
Repeated measures ANOVA revealed a significant main effect of group, [F(1,26) 
= 68.75, p < 0.0005], a significant effect of age, [F(2,52) = 24.16, p < 0.0005], 
and a significant group by age interaction, [F(2,52) = 27.84, p < 0.0005]. 
 
Results from Forebrain Study 
Astrocyte activation is an early stage phenomenon 
 Astrocyte activation, as identified by GFAP upregulation, is one of the first 
pathological changes observed in the PPT1-/- brains (Figure 10).  The forebrains 
from PPT1-/- and WT mice at 1, 3, 5, and 7 mos. of age were stained with GFAP.  
By 3 mos. of age, a statistically significant increase in GFAP staining was present 
Figure 10.  Early astrocyte activation precedes neuronal loss.  GFAP staining in 1, 3, 5, 
and 7-month-old PPT1-/- and 7-month-old WT brains. Focal areas of GFAP upregulation 
occur in the PPT1-/- brain beginning at 1-3 months of age.  Specifically, there is a notable 
increase in GFAP staining in the cortex, thalamus, and cerebellum of PPT1-/- mice.  The 
intensity and distribution of GFAP increases as the PPT1-/- mice age.  
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in the PPT1-/- forebrain, most notably within the cortex and thalamus (Figure 
11A). Initially, diffuse staining was present across all cortical laminae, in multiple 
regions of the cortex (i.e. motor, somatosensory, visual).  As the mice aged, the 
intensity and distribution of GFAP staining increased.  In contrast to the cortex, 
GFAP staining in the thalamus was more localized to individual thalamic nuclei.  
By 3 mos. of age, the lateral geniculate (LGN), medial geniculate (MGN), ventral 
posterior (VPM/VPL), mediodorsal (MD), central medial (CM), and reticular 
thalamic (Rt) nuclei were all densely stained.  As the mice aged, GFAP staining 
increased in intensity but also spread to include adjacent thalamic regions.  By 7 
mos. of age, the entire forebrain in the PPT1-/- mouse contained astrocyte 
activation.   
Neuronal loss in the thalamus  
 In the PPT1-/- forebrain, the thalamus is one of the first areas to undergo 
neuronal loss.  Neuronal loss in the thalamus is progressive in nature and 
specific to individual nuclei.  The LGN, part of the visual center, is the first 
nucleus to degenerate at 3 mos of age.  Neuronal loss in the remainder of the 
thalamic nuclei, including the MGN, VPM/VPL, and Rt, did not begin until 5 mos. 
of age.  Thus, these data indicate that neuronal loss in the thalamus is a later 
stage phenomenon beginning at 5 mos. of age.  
Cortical atrophy and neuronal loss 
 Although cortical thinning is one of the key elements of disease in INCL, 
this pathological change is a later stage phenomenon.  A statistically significant 
decrease in cortical thickness is not present until 5-7 months of age (summarized 
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in Figure 11B).    Also, cortical atrophy is not uniform but varies depending upon 
the region assayed.  For example, cortical thinning was present in the motor, 
visual, and auditory cortex, where no statistically significant change in cortical 
thickness was found in the somatosensory or entorhinal cortex.  Furthermore, the 
A C 
Figure 11.  Summary of Forebrain Pathology in the PPT1-/- mouse.  (A) Threshold analysis 
of GFAP stained images in the S1BF cortex demonstrates a quantitative increase in staining as 
the PPT1-/- mice age.  By 3 mos. of age, this is a significant increase when compared to WT 
brains.  (B)  A summary of the time course of significant neuronal loss (p<0.05 level) in the 
forebrain.  Neuronal loss is first observed in the thalamus, with neuronal death occurring in 
cortical relays later.  (C) F480 threshold analysis demonstrates that microglia activation is a late 
stage phenomenon in the S1BF cortex.  A significant increase in F480 staining begins at 5 mos. 
in the PPT1-/- mice but steadily increases as the mice age.  
B 
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visual cortex is the first region to demonstrate atrophy at 5 mos. of age, while the 
motor and auditory cortex do not degenerate until 7 mos. of age. 
 Quantitation of neuronal number reinforced the finding that cortical 
degeneration is a late stage phenomenon.  Neuronal loss is first seen in the 
visual cortex at 5 mos. of age.  However, neuronal loss occurs in the 
somatosensory cortex at 7 mos. of age.  These data demonstrate that cortical 
atrophy and neuronal loss occur subsequent to neuronal loss in their thalamic 
relays.    
Microglial reactivity is a late stage phenomenon 
 While astrocyte activation is an early stage phenomenon, microglial 
activation occurs during the later stage of disease (Figure 11C).  Microglial 
reactivity, as visualized by F4/80 staining, was not significantly elevated until 5 
mos. of age.  Prior to that time, little or no reactive microglia were present in the 
brain suggesting that microglia reactivity occurs in response to 
neurodegeneration.    Furthermore, the number of activated microglia increased 
in both the thalamus and cortex as the mice age. 
Seizure Activity 
 PPT-/- and WT mice at 6, 6.5, 7 and 7.5 mos. of age were monitored by 
EEG recordings and video surveillance for spontaneous seizure activity (Figure 
11).  No seizure activity was present in PPT1-/- mice prior to 7 mos. of age.  At 7 
mos. of age, only 50% of all PPT1-/- mice had seizures while 100% of 7.5 mos. 
old mice had seizures.  There was no change in seizure duration or frequency in 
the 7 or 7.5 mos. old mice.  The interictal EEG tracings were scored for all  
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Figure 12.  Progressive development of the seizure phenotype in PPT1-/-mice. (A) 
Representative example of a seizure recorded in a PPt1−/− mouse by two channel EEG. 
(B) Seizures were not evident in PPT1−/− mice until 7 months of age and were present in 
all mutant mice by 7.5 months of age, but were not present in age-matched controls (+/+). 
There was no significant difference between mutant mice in the frequency or duration of 
seizures at 7 and 7.5 months of age. Graded scoring of EEG recording traces also 
revealed a significant worsening of the interictal background EEG in mutant mice above 7 
months of age, compared to mutant mice at 6 and 6.5 months of age and age-matched 
controls (***p < 0.001, ANOVA with post hoc Tukey–Kramer multiple comparisons). 
 44 
animals tested.  There were no significant differences in the interictal EEG 
tracings of 6 and 6.5 months PPT1-/- mice when compared to WT.   However, 
with the onset of seizure activity, the background EEG patterns were abnormal 
by 7-7.5 mos. of age.   
 
Discussion 
 Although pathological changes within the PPT1-/- forebrain at an end 
stage of disease were described in detail (Bible et al., 2004; Griffey et al., 2004), 
little is known about the morphological and functional changes localized to the 
hindbrain.  Since reports of INCL patients describe profound cerebellar pathology 
(Haltia et al., 1973a; Haltia et al., 1973b) and motor deficits (Santavuori et al., 
1974), a complete characterization of the disease progression within the PPT1-/- 
cerebellum is essential.  Our findings demonstrate that substantial pathology 
exists within the PPT1-/- cerebellum, consistent with the human course of 
disease.  At an end stage of disease, there was significant cerebellar atrophy, 
suggesting profound cell loss in the PPT1-/- cerebella.  We performed silver 
degeneration staining to investigate which aspects of the cerebellum were most 
affected.  Staining of the cerebellar white matter was first observed, suggesting 
the major afferent and efferent projections were undergoing widespread 
degeneration.  Similarly, the molecular and Purkinje cell (PC) layers were 
argyrophillic, identifying ‘patches’ of degenerating PC bodies and dendritic 
arbors.  As described by Sarna and Hawkes (2003), PCs in the cerebellum are 
highly organized into parasagittal bands (based on zebrin II immunoreactivity), 
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which carry their own molecular fingerprint, and are differentially susceptible to 
toxic insults.  Silver staining suggests that specific classes of PPT1-/- PCs are 
more susceptible to cell death than others. 
Quantification of the PC layer showed a trend towards early neuronal loss.  
As described above, the death of PCs throughout each lobe was not random but 
rather a stereotyped wave of cell death beginning in the anterior lobes of the 
cerebellar vermis and later affecting the posterior lobes.  Although an increased 
sensitivity of certain classes of Purkinje cells is described in cerebellar mutants, 
lysosomal storage diseases (LSDs) with a cerebellar involvement preferentially 
affect the anterior lobes.  Other LSDs such as Nieman Pick Type A/B (Macauley 
et al., 2008a; Macauley et al., 2008b; Sarna et al., 2001), Nieman Pick Type C 
(Sarna and Hawkes, 2003), and late infantile neuronal ceroid lipofuscinosis 
(Chang et al., 2008; Sleat et al., 2004) detail a vulnerability of the PCs in the 
anterior lobes to cell death.  Some have postulated that increased levels of 
metabolic enzymes (Slemmer et al., 2007), increased glutamate transporter 
expression (EAAT4) (Welsh et al., 2002) and the presence of small heat shock 
proteins (Armstrong et al., 2000, 2001) is thought to be neuroprotective for PCs 
in the posterior lobes. 
Although some PCs are initially more resistant to toxic insults in INCL, the 
posterior lobes still become affected later in disease progression.  This 
phenomenon is consistent with other LSDs, but dissimilar to other cerebellar 
mutants (reviewed in (Sarna and Hawkes, 2003).  Even if a subset of PCs 
survives longer than others, we hypothesize that their function is compromised 
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based on the morphological changes observed (Figure 3).  Electrophysiology 
experiments are needed to evaluate surviving PCs. 
Consistent with PC loss in the PPT1-/- cerebellum, there was an age 
dependent decline in rotarod performance.  As PCs begin to die at 3 mo. of age, 
there is a concurrent decrease, although not significant, in PPT1-/- performance 
on the rotarod, which worsens with age.  Significant performance deficits 
(p≤0.05) on the constant speed rotarod are seen at 5 mos. of age, which 
coincides with a trend towards Purkinje cell loss that becomes significant by 6 
mos. of age.  These data demonstrate a strong relationship between cerebellar 
pathology and motor function, a phenomenon seen in other LSDs (Macauley et 
al., 2008). Furthermore, these findings correlate with the loss of neurons within 
motor pathways in the basal ganglia and thalamus (Kielar and Cooper, 
unpublished observations), which may also contribute to this phenotype.    
In contrast to PC loss, apoptotic cell death in the granular cell layer is a 
later stage phenomenon.  These data illustrate a selective vulnerability of 
cerebellar neurons to cell death, an important consideration for therapeutic 
delivery and timing. 
Recent reports on the NCLs (Bible et al., 2004; Chang et al., 2008; Kielar 
et al., 2007; Pontikis et al., 2005) demonstrate that gliosis occurs early in disease 
pathogenesis (reviewed in (Cooper et al., 2006).  Similarly, activation of the 
PPT1-/- Bergmann glia was the first cerebellar change.  Gliosis is a common 
component of many neurodegenerative disorders, yet it remains unclear whether 
this process is helpful or harmful to a chronically diseased CNS.  GFAP 
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upregulation is used as a marker of gliosis, yet its exact role in CNS disease 
remains uncertain.  We hypothesize that an early stage gliosis occurs for several 
reasons.  First, astrocyte activation is occurring in response to altered neuronal-
glial interactions (see below). In response to neuronal or glial stress, astrocytes 
shift roles from a quiescent to a reactive astrocyte early in INCL.  We 
hypothesize this shift stabilizes glutamatergic synapses to maintain the health of 
the CNS.  Thus, we hypothesize that activated Bergman glia are modulating 
neuronal-glial interactions in an effort to prevent CNS damage.  Secondly, we 
hypothesize that early stage astrocyte activation occurs as an anti-inflammatory 
mechanism within the CNS and at the gliovascular unit.  We postulate reactive 
astrocytes restrict access of systemic immune cells to the CNS via modulation of 
the blood brain barrier and/or chemokine signaling.  
Although INCL is described as a neurodegenerative disorder, there is 
prominent astrocyte pathology in the PPT1-/- cerebellum, a phenomenon likely 
independent of astrocyte activation.  As previously reported, normal astrocytes 
express PPT1 (Haltia, 2003; Margraf et al., 1999), and PPT1-deficient astrocytes 
accumulate GRODs (Galvin et al., 2007).  Our studies demonstrate a decrease in 
S100ß staining at early stages in PPT1-/- mice, most notably in the Bergman 
glia, suggesting a primary pathology in astrocytes.  Interestingly, S100ß staining 
is typically upregulated, not down regulated in CNS injury (i.e. neurodegenerative 
disorders, traumatic brain injury, etc.), (Goncalves et al., 2008; Griffin et al., 
1995; Mrak and Griffinbc, 2001; Rothermundt et al., 2003; Wainwright et al., 
2004).  This reduction of S100ß in astrocytes could be due to the secretion of 
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S100ß into the extracellular space, a neurotoxic event in the adult brain 
(reviewed in Donato, 2003).  Alternatively, the loss of S100ß staining may 
represent astrocytic cell loss.  To investigate this, we stained PPT1-/- cerebella 
for glutamine synthetase, an astrocyte specific enzyme important for glutamate-
glutamine recycling.  GS staining in the Bergman glia was decreased or largely 
absent in the PPT1-/- cerebellum, suggesting that astrocyte dysfunction or cell 
loss is a prominent feature in disease pathogenesis.   
GLAST staining further illustrated pathological changes in astrocytes.  
GLAST, an astrocyte specific glutamate transporter, is responsible for glutamate 
clearance at the synaptic cleft.  An overall decrease in GLAST expression was 
observed in the aged PPT1-/- cerebellum.  Furthermore, specific loss of GLAST 
is observed in the Bergman glia circumscribing PCs.  Although comparable levels 
of GLT-1 were observed in the PPT1-/- cerebellum, GLAST is the main 
glutamate transporter in Bergman glia, thus demonstrating a potential disruption 
in glutamate recycling in the PPT1-/- cerebellum. Furthermore, localized changes 
in the expression of glutamate and both astrocytic and neuronal glutamate 
transporters are also evident in the thalamus, basal ganglia and hippocampus 
(Kielar and Cooper, unpublished observations), suggesting that altered 
glutamate/glutamine cycling may be an important feature of INCL pathogenesis. 
Although changes in astrocytes and neurons occur at an early stage in 
INCL, changes in microglia and oligodendrocytes occur later.  As the mice age, 
there is an increase in F4/80+ cells in the CNS as well as changes in their 
morphology (Figure 7A,B).  We hypothesize that microglial activation is initially 
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mounted in the PPT1-/- cerebellum to clear cellular debris.  As the mice age, 
there is a secondary macrophage infiltration in INCL where circulating immune 
cells invade the PPT1-/- CNS.  It will be important to determine the relationship 
between these events, neuron loss, and blood brain barrier permeability.   
Demyelination is seen in the aged PPT1-/- cerebellum.  At autopsy, 
patients with INCL suffer a near complete loss of myelin in the CNS (Haltia, 
2003).  Not surprisingly, we found atrophy of the cerebellar white matter tracts as 
well as a loss of myelin components, such as CNPase (data not shown), in the 
PPT1-/- cerebellum.  Whether this demyelination is due to the axonal death of 
PCs or a primary oligodendrocyte dysfunction needs further investigation. 
The temporal-spatial characterization of the cerebellum successfully 
identified a time line for cellular pathology in the PPT1-/- brain (Figure 12).  The 
first pathological change observed in the PPT1-/- cerebellum is astrocyte 
activation at 1-3 months of age.  This change preceded neuronal loss, in either 
the Purkinje cell or granular cell layers.  By 5-7 mos. of age, there was a 
significant neuronal loss throughout the cerebellum concurrent with other 
changes in the glial population.  Specifically, by 7 mos. of age, there appears to 
be loss of the Bergmann glia, frank demyelination in the cerebellar white matter, 
and late stage microglial reactivity.  Interestingly, the motor deficits observed in 
the PPT1-/- mouse correlated with neuronal loss as a mid to late stage event.   
 A similar time line occurred regarding studies performed on the PPT1-/- 
forebrain (Figure 13).  Similar to the cerebellum, the first pathologic change 
observed was astrocyte activation in both the cortex and thalamus of PPT1-/- 
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mice at 3 mos. of age.  Subsequently, there was localized neuronal loss in 
thalamic nuclei were astrocyte activation had occurred.  Following neuronal loss 
in the thalamus, cortical atrophy and neuronal loss occurred in the PPT1-/- brains 
at 5-7 mos. of age.  Neurodegeneration correlated with an increase in microglia 
reactivity in both the cortex and thalamus.  The onset of seizure activity and 
changes in the interictal EEG pattern occurred at 7 mos. of age, coinciding with 
neuronal loss in cortex and thalamus. 
 These studies provide a comprehensive characterization of cellular 
pathology and its relationship to behavioral dysfunction in INCL.  We 
demonstrate that cellular pathology is not restricted to neurons, and that a 
Figure 13.  Summary of disease progression in the PPT1-/- mouse.  Disease progression is 
broken down into  3 stages- early (1-3 mos.), mid (3-5 mos.), and late (5-7 mos.).  During the 
early phase of disease, the first pathological change observed is astrocyte activation, delineated 
by GFAP upregulation.  Neuronal loss within the thalamus begins during the mid stage of 
disease, with neuronal loss in the cortex to follow.  Finally, at an end stage of disease, there is 
microglial activation and functional deficits in the PPT1-/- mice.  
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concurrent glial involvement, most notably in astrocytes, exists.  We demonstrate 
that astrocyte activation is one of the first pathological changes observed in 
either the forebrain or hindbrain of PPT1-/- mice.  With a better understanding of 
how the disease progresses in INCL, we can identify possible avenues for 
intervention in future therapy studies.  Since clinical trials for LINCL and INCL are 
ongoing (Sondhi et al., 2008; Sondhi et al., 2005; Taupin, 2006; Worgall et al., 
2008; Zhang et al., 2001), our studies identify the need to target therapies not 
only to the forebrain of patients suffering from INCL, but also to the hindbrain.  It 
also provides evidence of profound glial involvement and thus necessitates the 
development of therapies aimed at treating both neuronal and glial dysfunctions. 
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as defined by GFAP upregulation,  
in a mouse model of INCL 
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Introduction 
 
Characterization studies in the PPT1-/- mice yielded valuable insights into 
the progression of CNS disease in INCL (Kielar et al., 2007; Macauley et al., 
2009).  Previous studies demonstrated that localized areas of astrocyte 
activation, as defined by an increase in glial fibrillary acidic protein (GFAP) 
expression, are the first pathological changes observed in the PPT1-/- brains.  By 
1-3 months of age, there is a significant increase in GFAP staining in the 
thalamus, cortex, and cerebellum. Interestingly, the thalamus, cortex, and 
cerebellum also suffer the greatest neuronal loss and regional atrophy 
subsequent to this early astrocyte activation. Thus, we hypothesize that astrocyte 
activation, in particular GFAP upregulation, plays an active role in the 
pathogenesis of INCL, given its temporal-spatial association with future sites of 
neurodegeneration.  By investigating the role of astrocyte activation and GFAP 
upregulation, we will determine whether gliosis is protective or harmful to the 
underlying neurodegeneration and functional deficits associated with INCL. 
GFAP Upregulation and Astrocyte Activation 
 Astrocyte activation, or reactive gliosis, although often described, is a 
poorly understood phenomenon in CNS injury and disease (Kalman, 2004; 
Pekny and Nilsson, 2005; Sofroniew, 2005).  Although GFAP upregulation is the 
classic biomarker of gliosis, the relationship between increased GFAP 
expression and functional changes remains unclear.  This ambiguity is partly 
because the role of GFAP as a key intermediate filament protein in astrocytes 
remains poorly understood (Messing and Brenner, 2003; Pekny, 2001).  As 
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important components of astroglial cells, intermediate filament proteins, such as 
GFAP, vimentin and nestin, are thought to regulate the shape, structure, and 
motility of astrocytes (Eng et al., 2000; Potokar et al., 2007).  More specifically, 
GFAP is also responsible for stabilizing astrocytic processes, organizing 
organelles within cytoplasm, as well as anchoring glutamate transporters (i.e. 
GLAST) to the plasma membrane (Sullivan et al., 2007).  Studies from GFAP-null 
mice infer that the GFAP protein is involved in the maintenance of the blood brain 
barrier, myelin, and neuronal synapses.  Beyond these generalized or inferred 
functions, the biological role of GFAP remains elusive.  Moreover, the role of 
GFAP in astrocyte activation, specifically, is unclear.   
Although the function of GFAP is poorly understood, the correlation 
between GFAP upregulation and astrocyte activation is clear and well described 
(Bates et al., 2002; Hafiz and Brown, 2000; Haltia, 2003; Kobayashi et al., 2002; 
Levine and Hoenig, 1972; Li et al., 2008; Murphy et al., 1992; Murray et al., 2006; 
Oberheim et al., 2008; Pekny and Nilsson, 2005; Renkawek et al., 1999; Vajda, 
2002).  When the CNS is subjected to an insult or injury, there is an increase in 
GFAP expression, which coincides with a shift from a quiescent astrocyte to an 
activated astrocyte.  In a healthy CNS, quiescent astrocytes are responsible for a 
variety of functions, beyond providing structural integrity to the brain.  Most 
notably, astrocytes maintain neuronal synapses via metabolic support, 
neurotransmitter uptake, and glutamate recycling (Mazzanti et al., 2001; 
Nedergaard et al., 2003; Perea et al., 2009; Ransom et al., 2003; Schousboe et 
al., 1997; Volterra and Meldolesi, 2005; Walz, 2000).  Astrocytes also form the 
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gliovascular unit and modulate the blood brain barrier (BBB)(Goldstein, 1987; 
Nedergaard et al., 2003).  In addition to neuron-glial and gliovascular 
interactions, astrocytes are joined via gap junctions to create an astrocyte 
syncytium responsible for the propagation of intracellular signals (Kielian and 
Esen, 2004).  In response to injury, quiescent astrocytes become “activated” or 
“reactive” and adopt a secondary set of functions (Aschner, 1998a, b; 
Daginakatte et al., 2008; Eddleston and Mucke, 1993; Heales et al., 2004; 
Maragakis and Rothstein, 2006).  Morphologically, reactive astrocytes upregulate 
intermediate filament proteins like GFAP, vimentin (vim), and nestin resulting in 
astrocyte hypertrophy (Pekny, 2001; Pekny and Nilsson, 2005).  Both the number 
and thickness of astrocytic processes increases giving these cells their star 
shaped, or more accurately, “bushy” appearance (Wilhelmsson et al., 2006).  
Beyond structural modifications, reactive astrocytes are transformed functionally; 
they clear cellular debris, form glial scars, express cytokines, and promote 
inflammation.  
Although the process of gliosis is well described, it is often debated 
whether these structural and functional changes in astrocytes are helpful or 
harmful to the injured CNS.  Reactive gliosis has largely been studied in models 
of acute trauma or injury (Pekny and Pekna, 2004; Sofroniew, 2009; Sofroniew et 
al., 1999).  Findings from these studies demonstrate that although reactive 
astrocytes form glial scars that contain a site of injury, these cells also limit 
regeneration of the CNS via both a physical (i.e. glial scar) and molecular (i.e. 
cytokines) barrier (Daginakatte et al., 2008; Ridet et al., 1997; Voskuhl et al., 
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2009).  Given the dichotomous nature of reactive astrocytes in acute injury, there 
is an inherent need to gain a better understanding of this phenomenon, 
specifically in chronic, neurodegenerative diseases.  
The GFAP-/-, Vimentin-/-, PPT1-/- (3KO) mouse 
Recently, a mouse model lacking the intermediate filament proteins (IFs), 
GFAP and vimentin, was created and can be utilized to address the relationship 
between structural alterations (i.e. GFAP upregulation) and functional changes 
(i.e. cytokine production, neurodegeneration, etc.) associated with astrocyte 
activation in CNS injury and disease (Pekny et al., 1999).  When left 
unchallenged, the GFAP-/-, Vim-/- double knockout (2KO) mice breed, develop 
normally and live a normal lifespan.  However, when the 2KO mice are exposed 
to CNS injury, the outcomes are rather complex.  In the case of mechanical 
stress (i.e. traumatic brain injury, retinal detachment, stroke, etc.), the 2KO mice 
showed a decreased structural stability in the absence of IFs resulting in more 
damage (Kinouchi et al., 2003; Lane and Pekny, 2004; Li et al., 2008; Lundkvist 
et al., 2004; Nakazawa et al., 2007; Pekny, 2001; Pekny and Pekna, 2004; 
Verardo et al., 2008).  Although the glial scar was less organized in these models 
of CNS trauma resulting in larger infarct volumes, several of these models report 
positive outcomes such as greater axonal sprouting, synaptic regeneration and 
faster wound healing.  In a model of retinal detachment, the 2KO demonstrated a 
reduction in monocyte infiltration, cytokine expression, and photoreceptor cell 
death.  Taken together, results from studies using 2KO mice help elucidate both 
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the positive and negative outcomes associate with reactive gliosis in models of 
CNS injury.   
Goals of Chapter 3 
To further our understanding of the role of astrocyte activation in INCL, we 
crossed the 2KO mouse to the PPT1-/- mouse, thus creating the GFAP-/-, 
Vimentin-/-, PPT1-/- triple knockout (3KO) mouse.  By knocking out GFAP and 
Vimentin, we hypothesized we would alter how astrocytes react to injury in a 
model of INCL.  In this study, we investigated the effects of altered gliosis in the 
PPT1-/- brain.  We determined that astrocyte activation plays a protective role in 
INCL and in its absence disease pathogenesis is accelerated.  In the 3KO brains, 
the hallmark characteristics associated with INCL, such as premature death, 
brain atrophy, cortical thinning, and neurodegeneration, are exacerbated 
compared to the PPT1-/- mice and controls.  Furthermore, the underlying 
mechanisms responsible for this accelerated phenotype include immune cell 
infiltration, cytokine upregulation, and a compromised gliovascular unit.  Taken 
together, the 3KO mouse provides valuable information concerning the role of 
astrocyte activation in INCL.   
 
Methods 
GFAP-/-, Vimentin-/-, PPT1-/- Mice 
The GFAP-/-, Vimentin (Vim) -/- double knockout (2KO) and PPT1-/- mice 
were created through standard genetic techniques as previously reported.  The 
GFAP-/-, Vim-/- mice (a kind gift from Milos Pekny, University of Goteborg, 
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Goteborg, Sweden) were crossed to the PPT1-/- mice (Griffey et al., 2005; Gupta 
et al., 2001) to create the GFAP-/-, Vim-/-, PPT1-/-, or triple knockout (3KO), 
mice.  For the purposes of these studies, 3KO, 2KO, PPT1-/-, and wildtype (WT) 
mice were generated and maintained at Washington University School of 
Medicine as an outbred colony.  Mouse genotypes were determined by PCR-
based assays.  Both male and female mice from each genotype were used in this 
study.  Animals were housed under a 12:12 hour light:dark cycle and were 
provided food and water ad libitum.  All procedures were carried out under an 
approved IACUC protocol from Washington University School of Medicine.  
Brain Weights 
 Six-month-old 3KO, 2KO, PPT1-/-, and WT mice (n=5-6 mice per 
genotype per age) were sacrificed via a lethal injection of euthasol and the brains 
harvested by a researcher blinded to both genotype and age.  A razor blade was 
inserted coronally between the forebrain and olfactory bulbs to remove the 
olfactory bulbs from the remainder of the brain.  Similarly, a coronal cut was 
made immediately posterior to the cerebellum, separating it from the medulla and 
spinal cord.  Care was taken to ensure that the cuts were flush with the front of 
the cerebrum and back of the cerebellum.  Each brain was weighed using an 
analytical balance.  Group differences in weights were analyzed using a repeated 
measure ANOVA with one between subjects’ variable (genotype), one within-
subjects variable (age), and subsequent pairwise comparisons.  Bonferroni 
correction was used to maintain alpha levels at 0.05 when multiple comparisons 
were conducted. 
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Autofluorescent Accumulation 
 Six-month-old 3KO, 2KO, PPT1-/-, and WT mice (n=3 mice per group) 
were used to quantify autofluorescent accumulation in the somatosensory barrel 
field (S1BF) cortex using epifluorescent microscopy (Bible et al., 2004; Kielar et 
al., 2007).  Briefly, mice were given a lethal injection of euthasol, the brains 
removed, and fixed for 48 hrs in 4% PFA in phosphate buffer.  Following fixation, 
the brains were cryoprotected in 30% sucrose, embedded in OCT, and sectioned 
coronally on a freezing cryostat at 20µm thickness.  Images from 3 serial 
sections through S1BF for each group were captured via a 20x objective and 
FITC filter on a Nikon microscope with a SPOT camera attached.  All variables 
associated with image capture, including exposure time, binning, and gain, were 
held constant for all groups.  Using ImageJ software, threshold analysis was 
performed to determine which pixels contained autofluorescent accumulation in a 
given image.  The percentage of pixels containing autofluorescent material was 
calculated for each image and reported as the area fraction. Three sets of area 
fraction measurements were captured for each of the 3 sections through S1BF in 
each of the 4 groups.  The average for each group was calculated. Statistical 
significance was assessed using an ANOVA followed by Bonferrini correction 
post-hoc test. 
Nissl Staining  
Nissl staining was performed on six-month-old 3KO, 2KO, PPT1-/-, and 
WT mice (n=3 mice per group).  Briefly, mice were given a lethal injection of 
euthasol, the brains removed, and fixed for 48 hrs in 4% PFA in phosphate 
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buffer.  Following fixation, the brains were cryoprotected in 30% sucrose, 
embedded in OCT, and sectioned coronally on a freezing cryostat at 20µm 
thickness.  Sections throughout the primary visual (V1) cortex were mounted on 
glass slides, placed on a warming plate for 1 hr. and allowed to thoroughly dry 
overnight at room temperature.  Sections were briefly rinsed in dH20, incubated 
in 0.5% cresyl violet for 2 mins., and rinsed with dH20.  The sections were then 
dehydrated via a series of alcohols and xylenes and coverslipped. 
Cortical Thickness 
Cortical thickness measurements were performed on Nissl stained tissue 
from 3KO, 2KO, PPT1-/- and WT brains (n=3 brains per group).  Images 
throughout V1 were captured at 10X magnification using an Olympus BX41 
microscope and Olympuis DP 20 camera.  Cortical thickness measurements 
were made from the boundary of the white matter to the pial surface for each 
brain, as delineated by Paxinos and Franklin and as previously described(Bible 
et al., 2004; Kielar et al., 2007).  A series of 10 individual measurements were 
made for each of 3 sections for each mouse (n=3 mice per group).   The mean 
cortical thickness measurement for each mouse was determined. Statistical 
significance was assessed using an ANOVA followed by Bonferrini correction 
post-hoc test. 
DeOlmos Cupric Silver Staining 
5-month-old 3KO, 2KO, PPT1-/-, and WT mice (n=2 per time point) as well 
as a time course of 3KO mice at 3, 5, and 6 mos. of age (n=2-3 per time point) 
were processed for deOlmos silver staining.  Briefly, the mice were deeply 
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anesthetized with euthasol and transcardially perfused with 4% 
paraformaldehyde in sodium cacodylate buffer. The brains were removed and 
post-fixed for 48 hours.  Each brain was embedded in a gelatin-based matrix 
(Switzer, 2000) and serial coronal sections (35 µm) were cut on a freezing 
microtome by Neuroscience Associates (Knoxville, TN).  Neuronal degeneration 
was visualized by staining with a modified cupric silver method of DeOlmos  
(DeOlmos & Ingram, 1972; Switzer, 2000).  A matrix of PPT1-/- and WT brains at 
identical levels in the coronal plane were stained simultaneously.  Every sixth 
section (210 µm interval) was stained with the silver method and adjacent 
sections stained with H&E. 
Blood Brain Barrier Permeability 
  Blood brain barrier (BBB) permeability was assessed in 7 mos. PPT1-/-, 
7 mos. WT, and 5.5 mos. 3KO (n=4 mice per group) using an Evan’s blue assay 
(Belayev et al., 1996; Young et al., 2004).  PPT1-deficient mice receiving a 
middle cerebral artery occlusion (MCAO), or stroke, served as a positive control.  
Mice were injected with 2% Evan’s blue in saline via a tail vein injection (4µl/ g of 
body weight).  After 30 minutes, the mice were transcardially perfused with PBS 
until both the perfusate and liver were clear (approximately 1-2 minutes).  The 
brains were removed, bisected, and weighed.  One hemisphere was placed in 
500µl of 50% trichloroacetic acid (TCA) solution and homogenized for 1 minute.  
Following centrifugation, the dye was extracted and diluted 1:3 in ethanol 
(ETOH).  To determine the concentration of Evan’s blue dye in samples, the 
fluorescence of each sample was read on a fluorescent spectrophotometer 
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(Hitachi F-2000; excitation of 620nm and emission at 680nm) and the 
concentration calculated based on external standards (100-500 ng/ml) per gram 
of tissue.   A one-way ANOVA was performed to determine statistical significant 
at the p<0.05 level, with Tukey’s Multiple comparison’s post-hoc test.          
Cytokine Assays 
To estimate the concentration of cytokines within the brain parenchyma, a 
Bio-Plex multiplex cytokine assay kit was used on 3mos. 3KO, PPT1-/-, 2KO, 
and WT mice (Bio-Rad laboratories, Hercules, CA).  The ELISA-based cytokine 
assay uses fluorescently labeled beads coated with cytokine-specific antibodies 
to detect cytokine levels in tissues (Hulse et al., 2004).  The 23-plex sample kit 
includes standards and antibodies for the following cytokines: IL1α, IL-1β, IL-2,  
IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, Eotaxin, G-
CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α, MIP-1β, RANTES and TNF-α. 
Briefly, mouse brains were transcardially perfused with PBS and homogenized in 
a solution consisting of 10 mM Tris, 150 mM NaCl, 1 mM Dithiotreitol, 0.2% 
Triton and 20 l/ml of Protease Inhibitor Cocktail (#P8340, Sigma, St. Louis, MO). 
The supernatant from brain homogenates was diluted to obtain a protein target 
concentration of 0.5-1.0 mg/ml and stored at -70 C. For the multiplex assay, the 
samples were processed as per the manufacturer’s instructions. The fluorescent 
beads were incubated with the brain homogenates, washed and then incubated 
with biotin-labeled antibody cocktail. The samples were then incubated with 
streptavidin-PE and the fluorescence values were read and analyzed by the flow 
cytometry based Bio-Plex 2200 system (Bio-Rad laboratories, Hercules, CA). 
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The concentration of the cytokine in each sample was estimated by using the 
standard curve generated for each cytokine by the standards supplied in the kit. 
Immunohistochemistry 
Triple KO, 2KO, PPT1-/- and WT mice were sacrificed via a lethal injection 
of euthasol and transcardially perfused with phosphate buffered saline (PBS) 
until the liver was clear.  The brains from 1, 3, 5, and 6 and 7 months old mice 
were removed and fixed in 4% paraformaldehyde in phosphate buffer for 48 
hours.  Subsequently, the brains were cryoprotected with 30% sucrose in tris-
buffered saline (TBS) and imbedded in OCT.  Brains were sectioned in the 
coronal plane throughout rostral-caudal axis using a freezing cryostat.  Adjacent, 
free floating sections were stained with the following antibodies: rat anti-CD31 
(PECAM; 1:50, BD Pharmingen), rat anti-CD45 (1:50, BD Pharmingen), rat anti-
CD3 (1:200; Abcam), and rabbit anti-Aquaporin 4(1:1000; Chemicon).  Briefly, 
sections were washed in tris-buffered saline (TBS), incubated in 1% H2O2 
(Sigma) to quench endogenous peroxidase activity, and rinsed thoroughly in 
TBS.  The tissue was blocked for 1 hour in 10% normal goat serum (NGS; 
Sigma), 0.25% Triton X-100 in TBS.  Sections were incubated overnight at 4˚C in 
primary antibodies in 5% NGS, 0.2% Triton X-100 in TBS.  The following day the 
sections were rinsed in TBS and incubated in secondary antibodies (1:200; 
Vector Labs) in 10% NGS, 0.1% Triton X-100 in TBS for 75 minutes.  The tissue 
was rinsed in TBS and then incubated in a peroxidase conjugated avidin-biotin 
complex (1:200; Vectastain Elite ABC kit, Vector Labs) for 1 hour at RT.  
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Antibody immunoreactivity was visualized with 3’-3’ diaminobenzidine and H2O2 
(DAB kit; Vector Labs) in TBS.  Sections were dehydrated and coverslipped.  
 
Results 
Longevity 
  While WT mice live a normal lifespan, the 3KO and PPT1-/- mice 
experience a premature death mimicking a clinical feature of disease in INCL  
(Figure 1).  All 3KO and PPT1-/- mice die by 27 weeks and 33 weeks, 
respectively.  Furthermore, the 50% mortality for the 3KO is 20 weeks of age 
compared to 30 weeks for the PPT1-/- mice.  Thus, the 3KO mice die earlier than 
Figure 1.  Lifespan of the GFAP-/-, Vimentin-/-, PPT1-/- (3KO) mice.  The 3KO mice die 
earlier than the 2KO, PPT1-/-, or wild type mice. The 3KO and PPT1-/- die by 27 weeks and 
33 weeks, respectively.  Furthermore, the 50% mortality rate for 3KO averages 20 wks while 
the PPT1-/- mice is 30 wks.  
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the PPT1-/- mice, in addition to the WT and 2KO mice.  This demonstrates an 
accelerated disease course in the 3KO mice compared to the PPT1-/- mice.      
Brain atrophy 
 Brain weights were used as a marker of overall brain atrophy.  Brains from 
3KO, 2KO, PPT1-/-, and WT mice were weighed at 3, 5, and 6 mos. of age 
(Figure 2).  At 3 mos. of age, there was no significant difference in brain weights 
among the groups tested (p<0.30).  Conversely, there was a significant decrease 
in brain weight at 5 mos. of age in the 3KO mice (p<0.027) compared to the 
either PPT1-/-, 2KO, or WT mice.  On average, the 3KO brains weighed 13.6% 
 
* 
Figure 2.  Brain atrophy in the GFAP-/-, Vimentin-/-, PPT1-/- (3KO) mice.  At 3 mos. of age, 
there is no significant difference in the brain weights between 3KO, 2KO, PPT1-/-, and WT 
mice.  However, the 3KO brains weigh significantly less than PPT1-/-, 2KO, and WT mice at 5 
mos. of age suggesting atrophy occurs at this time.  By 6 mos. of age, both the 3KO and 
PPT1-/- brains weigh significantly less than WT and 2KO brains ( * = p<0.05). 
* 
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less than WT brains at 5 mos.  By 6 mos. of age, there was a significant 
decrease in the brain weights of both the 3KO and PPT1-/- mice compared to 
WT and 2KO mice (p<0.001).  The 3KO and PPT1-/- brains decreased in weight 
by 20% and 17%, respectively, when compared to WT brains.  These data 
demonstrate an overall brain atrophy in 3KO mice beginning at 5 mos. of age, 
which precedes the atrophy seen in the PPT1-/- brain at 6 mos. of age.     
Cortical Thinning 
 Upon gross examination, the primary visual cortex (V1) of 3KO and PPT1-
/- mice appeared atrophied in comparison to 2KO and WT brains (Figure 3A).  
Therefore, we measured cortical thickness in V1 at 6 mos. of age in the 3KO, 
2KO, and WT mice (Figure 3B).  There was a significant difference in cortical 
thickness between all groups measured (p<0.001).  At 6 months of age, the 3KO 
WT 2KO 3KO PPT-/- 
A B 
p<0.001 
Figure 3.  Cortical thinning in the GFAP-/-, Vimentin-/-, PPT1-/- mice.  (A) Representative images 
from the visual cortex (V1) of WT, 2KO, PPT1-/-, and 3KO mice. Upon gross examination, V1 of 3KO 
and PPT1-/- mice appeared atrophied in comparison to 2KO and WT brains.  (B) Quantification of 
cortical thickness in the WT, 2KO, PPT1-/-, and 3KO mice.  There is a significant difference in cortical 
thickness between all groups (p<0.0001).  The visual cortex of 3KO mice is thinner than the V1 
cortex of PPT1-/-, 2KO, and WT mice.   
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mice had a mean cortical thickness of 533.2µm, compared to WT, 2KO, and 
PPT1-/- brains, which were 719.6µm, 687.8µm, and 583.2µm, respectively.  
Thus, there was a 25.9% decrease in cortical thickness of 3KO brains compared 
to WT, while the PPT1-/- brains only suffer an 18.9% loss.  Therefore, cortical 
thinning in the 3KO is more severe than in the PPT1-/- or 2KO brains when 
compared to WT.  
Autofluorescent Accumulation 
 Accumulation of an autofluorescent substrate throughout the neuraxis is a 
hallmark of INCL.  Therefore, we investigated whether the 3KO brains had a 
demonstrable load of autofluorescent material.  Qualitatively, the 3KO and PPT1-
/- brains both contained autofluorescent storage material throughout the brain at 
6 mos. of age.  Autofluorescent substrate accumulated intracellularly in the 3KO 
brain in a pattern similar to the PPT1-/- mouse (Figure 4A). A low level of 
autofluorescent material was detected in the WT and 2KO, largely due to the 
presence of autofluorescent red blood cells contained within the vasculature.  To 
determine the level of storage material in the CNS, we quantified 
autofluorescence in the S1BF cortex of 3KO, 2KO, PPT1, and WT brains (Figure 
4B). There was a significant increase (p<0.001) in autofluorescent accumulation 
in both the PPT1-/- and 3KO brains compared to WT and 2KO.  Furthermore, 
there was a significant difference (p<0.0023) in the levels of autofluorescent 
substrate in PPT1-/- and 3KO mice.  More specifically, there was a 21% increase 
in autofluorescence in the S1BF cortex of PPT1-/- mice compared to the 3KO 
mice.  
 68 
WT 2KO PPT1-/- 3KO 
A 
B 
Figure 4.  Autofluorescent accumulation in the GFAP-/-, Vimentin-/-, PPT1-/- mice.  
(A) Representative images of the somatosensory barrel field (S1BF) cortex in WT, 2KO, 
PPT1-/-, and 3KO mice. Autofluorescent accumulation is present in both the 3KO and 
PPT1-/- mice compared to the 2KO and WT brains.  (B) There is a significant increase 
(p<0.0001) in autofluorescent material in the PPT1-/- and 3KO mice compared to WT and 
2KO mice.  Interestingly, there is a significant decrease in autofluorescent load in the 3KO 
mice compared to PPT1-/- mice (p<0.0023).   
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Neurodegeneration 
 Given that neuronal loss is a hallmark feature of INCL, de Olmos cupric 
silver staining was performed to assess the levels of neurodegeneration present 
in the 3KO brains (Figure 5).  When neurons undergo degeneration in the CNS, 
they have a high binding affinity for silver causing both cell bodies and processes 
to appear ‘blackened’ with this staining method.  Thus, we first examined the 
distribution of silver staining in the 3KO brain.  Previous studies in the PPT1-/- 
mice demonstrated the neuronal loss was largely found within the thalamus, 
cortex, cerebellum, and hippocampus of aged mice (Griffey et al., 2005; Griffey 
et al., 2006).  In fact, the distribution of neurodegeneration in the 3KO brains 
mirrored the pathology observed in the PPT1-/- brains.  Globally, degenerating 
neurons were present within the cortex, thalamus, hippocampus, and cerebellum 
at 5 mos. of age (Figure 5A).  In the cortex, ‘blackened’ cell bodies of dying 
neurons are primarily localized to layers II & V while degenerating axons litter the 
cortex.  Diffuse staining throughout the thalamus is present, most notably in the 
afferent and efferent fibers associated with thalamic nuclei.  Intense staining is 
found the cerebellum, with the cerebellar white matter densely stained.  
Additionally, darkened cell bodies are found within the Purkinje cell layer 
demonstrating degeneration in the 3KO cerebellum similar to the PPT1-/- brain.  
Darkly stained profiles were also found in the CA1 field of the hippocampus as 
well as degenerating processes filling the stratum radiatum.  Based on these 
findings, the distribution of neurodegeneration within the 3KO brains mimics the 
observations found in the PPT1-/- mice. 
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Figure 5.  Neurodegeneration, as visualized by silver degeneration staining, in the GFAP-/-, 
Vimentin-/-, PPT1-/- mice. (A) Representative images from the cortex, thalamus, cerebellum, and 
hippocampus of 5 mo. old 3KO mice.  Darkly stained cell bodies are present in the cortex and CA1 
field of the hippocampus, while degenerating axons are present in the thalamus and cerebellar 
white matter tracts.  (B) Time course of neurodegeneration in the 3KO mouse.  As the 3KO mice 
age, the intensity and distribution of silver staining increases demonstrating an increase in 
neurodegeneration.  Interestingly, the level of degeneration in a 7 mos. PPT1-/- brain appears 
comparable to the 3KO at 5 mos. of age.  (C) Comparison of silver staining at 5 mos. of age in the 
WT, 2KO, PPT1-/-, and 3KO mice.  At 5 mos. of age, there is no staining within the WT or 2KO 
brains.  Staining in the PPT1-/- brain is localized to the corpus callosum, hippocampus, and 
thalamus.  In the 3KO brain, staining in these regions appears more intense, suggesting an 
accelerated disease course in the 3KO brains.     
 71 
 In addition to the regional distribution of neurodegeneration, we also 
investigated the temporal progression of disease in the 3KO at 3, 5, and 6 mos. 
(Figure 5B).  As the 3KO mice age, there is increase in silver degeneration 
staining throughout the thalamus, hippocampus, and cortex.  Although silver 
staining is present in the cortex and thalamus at 3 mos. of age, the hippocampus 
is relatively spared.  As the mice age, darkly stained profiles are apparent in the 
hippocampus as well as the cortex.  Similarly, staining in the corpus callosum 
increases in intensity by 5 mos.  By 6 mos. of age, the entire 3KO brain appears 
blackened.  In areas where individual degenerating axons were easily reconciled 
(i.e. pyramidal neurons from the CA1 field of the hippocampus), the 6 mos. 3KO 
brains now appear densely stained and indiscernible.  The neurodegeneration 
occurring in the 6 mos. 3KO is more advanced than a PPT1-/- brain at 7 mos. of 
age (Figure 5B), again illustrating the accelerated disease phenotype in the 3KO 
mice.     
In addition to characterizing the distribution and progression of pathology 
in the 3KO, we sought to compare the relative severity of pathology in the 3KO 
mouse to the PPT1-/-, 2KO, and WT mice (Figure 5C).  Little or no silver staining 
was present within either the 2KO or WT brains.  In the PPT1-/- brain, blackened 
cellular profiles were apparent within the cortex and CA1 field of the 
hippocampus.  In addition, blackened axonal projections filled the thalamus and 
corpus callosum.  Qualitatively, the same pattern of staining was present in the 
3KO mice but it appears to be stained more intensely.  In particular, the corpus 
callosum and statum radiatum appeared more densely stained in the 3KO 
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compared to PPT1-/- mice.  Furthermore, the distribution and intensity of staining 
increased in the 3KO cortex and thalamus.  Overall, the level of 
neurodegeneration in the 3KO brains seems greater than that of the PPT1-/- 
brains. 
Immune cell infiltration 
  H&E stained sections of 3KO brains displayed a small cell infiltrate not 
present in either the PPT1-/-, 2KO, or WT brains (data not shown).  
Hypothesizing the small cell infiltrate was composed of blood-derived leukocytes, 
we performed CD45 staining, a pan-leukocyte marker, in the 3KO, 2KO, and WT 
brains (Figure 6).   At 5 mos. of age, the 3KO brains had a qualitative increase in 
the number of CD45-positive profiles throughout the neuraxis compared to PPT1-
/- and controls (Figure 6A).  Although some CD45-positive profiles were present 
within the PPT1-/- brains, the staining was considerably less than that of the 3KO 
brains.  Furthermore, CD45+ staining was absent from the WT controls. 
 At higher magnification, it was clear that the CD45-positive cells within the 
3KO brains were morphologically diverse (Figure 6B, C, D).  Some of the cells 
resembled microglia (Figure 6B), granulocytes or macrophages (Figure 6C), and 
lymphocytes (Figure 6D).  To ascertain what CD45 population was invading the 
brain parenchyma, we stained for different cell lineages with lineage specific 
markers.  Using Iba-1 staining for microglia or brain macrophages, we 
demonstrated a large number of Iba-1 positive cells in both the PPT1-/- and 3KO 
brains (Figure 6E).  The intensity of staining per cell appeared qualitatively 
increased in the 3KO brains, although no overt increase in the number of cells  
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Figure 6.  Immune cell infiltration into the 3KO CNS.  (A) CD45, a leukocyte marker, staining 
in the 5 mo. 3KO, 5 mo. PPT1-/-, and 7 mo. WT cortex.  Notice the large number of CD45+ cells 
within the 3KO cortex in comparison to either the PPT1-/- or WT brains.  At higher 
magnification, the CD45+ cells appeared to be morphologically similar to microglia (B), 
granulocytes or macrophages (C), and lymphocytes (D).  (E) Staining with lineage-specific 
markers demonstrated a large population of Iba-1+ microglia and macrophages within the 
PPT1-/- and 3KO brains.  Interestingly, there was a large population of CD3+ T cells (small 
intensely staining foci) within the 3KO brains, when compared to PPT1-/- and WT. 
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stained was appreciable.  Interestingly, CD3 staining, a T cell marker, 
demonstrated a marked increase in the number of CD3+ cells within the 3KO 
brains compared to either PPT1-/- or WT (Figure 6E).  Although CD3+ cells were 
present in low amounts in the PPT1-/- brain, the number of CD3+ profiles in the 
3KO was considerably higher than in PPT1-/- mice. 
Blood brain barrier permeability and the gliovascular unit 
 To detect possible perturbations in the blood brain barrier (BBB), a 
quantitative Evan’s blue (EB) assay was employed (Figure 7). When delivered 
intravenously, EB binds albumin and circulates throughout the blood stream. If 
the BBB is disrupted due to an insult or injury, the EB/albumin complex will cross 
the BBB into the brain parenchyma and the levels of EB within the brain can be 
quantified.  PPT1-/-, 3KO, and WT mice were injected intravenously with EB dye 
and the concentration in the brain was analyzed.  To serve as a positive control 
for BBB permeability, WT mice were given middle cerebral artery occlusions 
(MCAO), a procedure known to disrupt the BBB (Belayev et al., 1996).  There 
was a significant (p<0.001) increase in EB concentration within the MCAO brain 
compared to the 3KO, PPT1-/-, or WT.  Interestingly, there was no significant 
difference (p< 0.1798) in EB concentration in either 3KO or PPT1-/- brains 
compared to WT mice, suggesting no overall perturbation of the BBB in the 3KO 
mice.  
 Although no gross disruption of the BBB was detected in the 3KO, we 
investigated the structural integrity of the gliovascular unit.  We immunostained 6 
mo. old 3KO and WT mice for aquaporin 4 and CD31 (PECAM).  Qualitative  
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Figure 7.  BBB integrity in the 3KO mouse.  (A) An Evan’s blue 
assay was performed to assess BBB permeability in the 3KO, PPT1-/-, 
and WT mice.  There was no significant difference in the amount of 
Evan’s blue detected in the brains of 3KO compared to PPT1-/-, or WT 
mice.  A middle cerebral artery occluded (MCAO) mouse served as a 
positive control for the assay.  (B) Alterations in the gliovascular unit of 
3KO mice was evident with aquaporin 4 (AQP4) and CD31 (PECAM) 
staining.  There was a redistribution in AQP4 staining in the 3KO mice 
compared to WT.  Similarly, the PECAM staining illustrated changes in 
the vascular in 3KO brains.    
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differences in aquaporin 4 staining, a water channel localized to the endfeet of 
astrocytes, were apparent in the 3KO mice compared to WT (Figure 7B).  In the 
WT cortex, aquaporin staining appears to outline the vasculature and localizes to 
the junction of the astrocytic endfeet and blood vessels.  In the 3KO mice, 
however, this intimate junction between the astrocytic endfeet and vasculature 
appears disrupted and is replaced by a more diffuse pattern of aquaporin 4 
staining throughout the cortex.  It remains unclear whether there is an actual 
decrease in the amount or merely an altered distribution of aquaproin 4 in the 
3KO brains.  Alterations in CD31 (PECAM) staining were also appreciable in 
3KO brains compared to WT.  In the WT brains, CD31 demarcated the vascular 
bed traversing through the CNS.  Although the size of vessle differed from vessel 
to vessel, the diameter of individual blood vessels appeared uniform in the WT 
brains (Figure 6B; inset).  Conversely, regions of CD31+ vessels in the 3KO mice 
appeared either shrunken, dysmorphic or “pinched” (Figure 7B; inset).  Together, 
CD31 and aquaporin 4 staining demonstrates changes in the gliovascular unit of 
3KO mice. 
Cytokine Levels 
 A panel of 23 cytokines was simultaneously evaluated in 3 mos. old 3KO, 
PPT1-/-, 2KO, and WT brains using a Bio-Plex cytokine assay system (Bio-Rad).  
Out of the 23 cytokines assayed, 13 analytes displayed increased expression in 
both 3KO and PPT1-/- mice compared to WT (Figure 8).   In all cases, cytokine 
elevation in the 3KO mice was greater than the PPT1-/- mice.  Many of the 
upregulated molecules (i.e. IL-3, IL-5, IL-6, IL-13, etc.) are traditionally secreted 
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by T cells and stimulate additional immune cell activation.  In addition, a number 
of the cytokines, such as MCP-1, MIP-1α, and MIP-1β, are secreted by 
monocytes and activate both monocytes as well as other immune cells.  There 
were 4 cytokines with greater than a 15-fold change in levels compared to WT 
brains.  These molecules include IL-17, IFN-g, MIP-1β, and RANTES, all of 
which a pro-inflammatory molecules.   
 
Figure 8.  Elevated cytokine levels in the 3KO brains.  The brains from 3 mos. old 3KO, 2KO, 
PPT1-/-, and WT mice were simultaneously assayed for 23 different cytokines.  Of those 
assayed, 13 cytokines were upregulated in the 3KO (green) and PPT1-/- (red) brains normalized 
to WT.  The 3KO brains contained elevated levels of cytokines in comparison to PPT1-/-.  IL-17, 
IFN-g, MIP-1β, and RANTES demonstrated greater than 15-fold higher cytokine levels than WT. 
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Discussion 
 Previous research demonstrated that the first histopathological change 
observed in the mouse model of INCL is astrocyte activation.  Astrocyte 
activation, as defined by GFAP upregulation, is present as early as 1-3 mos. of 
age in the thalamus, cortex, and cerebellum of PPT1-/- mice (Kielar et al., 2007; 
Macauley et al., 2009).  Subsequent to this early stage gliosis, there is significant 
neuronal loss in the same regions.  Therefore, we hypothesized that astrocyte 
activation plays a role in the disease pathogenesis of INCL.  However, one 
question remained: was astrocyte activation a helpful or harmful process in 
INCL? 
 To investigate the role of astrocyte activation in INCL, we created the 
GFAP-/-, Vimentin-/-, PPT1-/- triple knockout (3KO) mouse.  Since astrocytes 
first respond to injury by upregulating the intermediate filament proteins, GFAP 
and vimentin, increased GFAP expression is viewed as the classic sign of 
astrocyte activation or gliosis (Kalman, 2004; Pekny and Nilsson, 2005; 
Sofroniew, 2005).  In addition, increased expression of IFs in activated astrocytes 
correlates with a change in the molecular profile and function of astrocytes.  
Typically responsible for homeostatic maintenance and structural support in the 
CNS (Ransom et al., 2003), astrocytes take on the additional role of an 
inflammatory-mediating cell responsible for cytokine secretion, scar formation, 
and the clearance of debris in the context of gliosis.  Since there was a strong 
correlation between the upregulation of IFs and the functional shift in astrocytes, 
we hypothesized that by knocking out GFAP and its co-polymerizing IF protein, 
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vimentin, we would alter the manner in which astrocytes respond to injury.  Thus, 
by creating the 3KO mouse, we could evaluate whether astrocyte activation is 
helpful or harmful in a mouse model of INCL. 
 Our first goal was to investigate whether the classic features of INCL were 
reproduced in the 3KO mice.  Since the brains from INCL patients display an 
overall atrophy, cortical thinning, autofluorescent accumulation, and widespread 
neurodegeneration, we chose to investigate these pathological changes in the 
3KO mouse.  Interestingly, we found that the 3KO mouse displayed the same 
pathological features as the PPT1-/- mice and patients with INCL.  The 3KO mice 
suffered premature death by 28 weeks of age compared to 2KO and WT mice.  
Similarly, there was both a global brain and regional atrophy observed in the 3KO 
mice compared to controls at an end stage of disease.  Furthermore, the brains 
from 3KO mice displayed an increase in autofluorescent material, a hallmark of 
INCL.  Most importantly, silver staining demonstrated that the regional 
distribution of neurodegeneration matched the pattern of pathology seen in the 
PPT1-/- or INCL brains.  These findings demonstrate that in the absence of the 
IF proteins, GFAP and Vimentin, the pathological changes associated with INCL 
are reproduced in the 3KO mouse.  Thus, the introduction of two novel mutations 
(i.e. GFAP and Vimentin deficiencies) onto the PPT1-/- background did not 
create a novel disease phenotype.  Therefore, the 3KO mouse is an excellent 
model to investigate the effects of altered astrocyte activation on clinical features 
of INCL.     
 Although the hallmarks of INCL are recapitulated in the 3KO mice, the 
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progression of disease is altered compared to the PPT1-/- mice.  In the absence 
of the IF proteins, GFAP and Vimentin, the time course of disease is accelerated 
compared to the PPT1-/- mice.  On nearly every parameter measured, the 3KO 
mice displayed either an early onset of disease (i.e. premature death & brain 
atrophy) or an increased severity of disease at a particular time point (i.e. cortical 
thinning & neurodegeneration).  This demonstrated that astrocyte activation is a 
protective feature of disease in INCL.  In the absence of GFAP and Vimentin 
upregulation, the disease phenotype present in the PPT1-/- mice displays an 
early onset and increased severity.     
The one notable exception to the accelerated disease course in the 3KO 
mouse is autofluorescent accumulation.  Although both the 3KO and PPT1-/- 
brains demonstrate an increase in autofluorescent storage compared to 2KO and 
WT mice, the 3KO mice have significantly less material compared to PPT1-/- 
mice. This finding has several possible explanations.  Most likely, there could be 
less autofluorescent material in the 3KO mice because there is greater 
neurodegeneration resulting in fewer cells to accumulate stored substrates.  
Conversely, it is plausible that the 3KO mice do not accumulate storage 
pathology as rapidly as PPT1-/- mice.  Thus, the causal relationship between 
autofluorescent accumulation and neurodegeneration remains poorly understood 
and warrants further study. 
In an effort to investigate the underlying mechanism causing the 
accelerated phenotype in 3KO mice, we investigated the presence of 
inflammatory cells within the 3KO brains. In fact, we detected the presence of 
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CD45-positive cells, or leukocytes, in the brains of 5-month-old 3KO mice, a 
phenomenon absent in the PPT1-/- brains at a comparable age.  Interestingly, if 
PPT1-/- brains at 7 mos. of age are stained with a CD45 antibody, CD45+ 
leukocytes are present in the brain.  Again, suggesting that the same disease 
processes are present in the 3KO but exacerbated when compared to the PPT1-
/- mice.  The CD45+ cells within the 3KO brains were morphologically diverse.   
Through cell lineage-specific markers, CD3 and Iba-1 staining, we showed a 
large T cell and monocyte population within the 3KO brains, respectively.  We 
hypothesize that the infiltration of T cells and monocytes is contributing to the 
accelerated disease course observed in the 3KO mice.  Other neurodegenerative 
disorders, such as multiple sclerosis (McCandless and Klein, 2007), Krabbe 
disease (Wu et al., 2001), and West Nile viral infection (Shrestha et al., 2003), 
demonstrate the presence of peripheral immune cells in the CNS and it is 
hypothesized that this phenomenon is playing an active role in disease 
pathogenesis (Chavarria and Alcocer-Varela, 2004; Lucas et al., 2006).    
To examine the possible mechanisms for T cell and monocyte entry into 
the CNS, our work focused on the blood brain barrier in the 3KO mice.  
Interestingly, the astrocytes that first display an increase in GFAP 
immunoreactivity are cells in intimate contact with the vasculature (data not 
shown).  Postulating that the integrity of the BBB was compromised in the 3KO 
mice, we investigated the ability of a large EB-albumin complex to cross the BBB.  
Interestingly, no gross perturbation of the BBB was appreciable in either the 3KO 
or PPT1-/-.  We further examined the BBB integrity by investigating the structural 
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composition of the gliovascular unit.  By staining the 3KO and WT brains with 
aquaporin 4 and CD31 (PECAM), we demonstrated both a redistribution in 
aquaporin 4 staining as well as dysmorphic blood vessels in the 3KO brain.  This 
suggests that there are alterations in the gliovasucular unit in the 3KO mice when 
compared to WT.  Changes in both aquaporin 4 and PECAM expression have 
been implicated in neurodegenerative diseases and disruptions in the BBB that 
facilitate leukocyte entry into the CNS (Chavarria and Alcocer-Varela, 2004; 
Nesic et al., 2006).  Based on these observations, we hypothesize that IFs are 
necessary for maintaining the gliovascular unit during astrocyte activation.  In the 
absence of intermediate filament proteins, the structural organization of the BBB 
becomes compromised and allows for leukocyte entry into the CNS, thus 
exacerbating disease. 
Given that the BBB is not only a structural barrier but also a molecular 
barrier, we sought to investigate the molecular signals expressed by the CNS 
that are responsible for the influx of leukocytes.  Therefore, we performed a Bio-
Plex mouse cytokine assay, which screens the levels of 23 different cytokine 
simultaneously.  At 3 mos. of age, there was a notable increase in 13 cytokines 
in both the 3KO and PPT1-/- brains.  In all cases, cytokine evaluations in the 
3KO mice were greater than those seen in PPT1-/- mice.  In addition to changes 
in the gliovascular unit, this finding demonstrates that increased cytokine 
expression could be responsible for the influx of peripheral immune cells into the 
CNS.   
Of the cytokines with increased expression levels, many of the molecules 
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(i.e. IL-3, IL-5, IL-6, IL-13, etc.) are traditionally secreted by T cells and 
responsible for the stimulation and activation of other immune cells (Doan et al., 
2007; Dong and Benveniste, 2001; Rengarajan et al., 2000).  Similarly, a number 
of the cytokines normally secreted by monocytes/macrophages, such as MCP-1, 
MIP-1α, and MIP-1β, are responsible for the activation of other immune cells 
(Cocchi et al., 1995).  Given the large T cell and monocyte populations within the 
3KO brains, it is not surprising that this set of cytokines is upregulated.  
Interestingly, several of the cytokines expressed in the 3KO and PPT1-/- brains 
are also routinely expressed by astrocytes during neuroinflammation, including 
IL-6, KC, GM-CSF, RANTES, and MCP-1 (Dong et al).  Although it is unclear 
what cells types are responsible for the elevated cytokine levels, it is clear that a 
large neuroinflammatory response is occurring within the CNS of 3KO brains.   
Of the cytokines upregulated, there were four cytokines with a greater 
than 15-fold increase in expression.  These molecules include IL-17, IFN-g, MIP-
1β, and RANTES.  Not surprisingly, IL-17, a pro-inflammatory molecule 
responsible for the induction of numerous cytokines (e.g. IL-6, GM-CSF) and 
chemokines (e.g. IL-8, MCP-1) in a variety of cell types (e.g. endothelial cells, 
macrophages), demonstrated a 17.9-fold increase in cytokine levels in the 3KO 
brains.  Similarly, interferon gamma (IFN-g), one of the most common pro-
inflammatory cytokines in the CNS during disease or injury, displayed 23.4-fold 
change compared to WT.  IFN-g is known to be a potent inducer of class II MHC 
expression in astrocytes, which is subsequently responsible for the activation of 
both T cells and macrophages.  Furthermore, production of IFN-g can damage 
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the BBB due to cytotoxic effects on endothelial cells (Chavarria).  Produced by 
macrophages, MIP-1β is a chemotactic cytokine responsible for the recruitment 
of granulocytes as well as the stimulation and release of additional cytokines by 
monocytes.  Interestingly, RANTES, often expressed by astrocytes, is another 
chemotactic cytokine responsible for the recruitment of T cells and other 
leukocytes to sites of inflammation.  Given the high level of expression of these 
four cytokines, it is not surprising that an invading leukocyte population was 
detected in the brains of the 3KO mice or that an increase in neurotoxic insults 
was appreciable in the CNS. 
  The goal of this study was to investigate the role of astrocyte activation, 
as defined by GFAP upregulation, in INCL.  To do so, we created the GFAP-/-, 
Vimentin-/-, PPT1-/- triple knockout mouse and investigated the effects of 
knocking out the intermediate filament proteins on the disease progression 
associated with INCL.  Although we found that PPT1-/- mice lacking GFAP and 
Vimentin displayed the classic features of INCL, the 3KO mice displayed a more 
accelerated course of disease compared to PPT1-/- mice alone.  The 3KO mice 
displayed either an early onset of disease (i.e. premature death & brain atrophy) 
or an increased severity of disease at a particular time point (i.e. cortical thinning 
& neurodegeneration) when compared to PPT1-/- mice.  To determine the 
underlying mechanisms contributing to this accelerated phenotype, we found a T 
cell and monocyte population in the brains of 3KO mice.  Although there was no 
overt disruption in the BBB, there were alterations in the gliovacular unit that may 
be responsible for leukocyte infiltration.  In addition to structural changes in the 
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BBB, we demonstrated increased cytokines are potentially responsible for the 
increased neuroinflammation in 3KO and ultimately the accelerated disease 
course.  Taken together, these data suggest that astrocyte activation, as defined 
by GFAP upregulation, plays a protective role in a mouse model of INCL.  
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Summary and Conclusions 
 Infantile neuronal ceroid lipofuscinosis (INCL) is a rare lysosomal storage 
disorder typified by prominent CNS involvement (Hofmann et al., 1999; Hofmann 
and Peltonen, 2001; Vesa et al., 1995).  INCL is caused by an enzyme deficiency 
in the lysosomal hydrolase, palmitoyl protein thioesterase 1 (PPT1).  In its 
absence, all cells throughout the CNS and viscera accumulate autofluorescent 
material (i.e. GRODs) to varying extents (Das et al., 1998; Hofmann et al., 2002; 
Mitchison et al., 1998; Mitchison et al., 2004; Vesa et al., 1995).  Normally 
diagnosed by 1.5 years of age, patients with INCL present with clinical features 
such as blindness, seizures, motor deficits, retinal defects, and mental 
retardation.  Underlying these clinical manifestations, pathological changes in the 
brain include an overall brain atrophy, cortical thinning, widespread 
neurodegeneration, astrocyte activation, and microglial reactivity.  Invariably, 
INCL is fatal and leads to death by 6 years of age (Haltia et al., 1973a; Haltia et 
al., 1973b; Haltia et al., 1995; Hofmann and Peltonen, 2001; Vanhanen et al., 
1997).  Currently, there is no efficacious treatment available for INCL.   
 Gupta and colleagues (2001) created a mouse model of INCL, the PPT1-/- 
mouse.  Initial characterization studies suggested that the mouse model of INCL 
recapitulates the human course of disease quite well(Bible et al., 2004; Griffey et 
al., 2004; Griffey et al., 2005; Griffey et al., 2006; Gupta et al., 2001).  At an end 
stage of disease, the PPT1-/- mice suffered brain atrophy, cortical thinning, 
widespread neurodegeneration, glial activation, retinal defects, motor deficits, 
and seizure activity; features similar to those found in patients with INCL.   
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Based on these results, we believe the PPT1-/- mouse is a valuable tool 
for investigating the disease pathogenesis of INCL.  Although the pathology of 
INCL patients at autopsy is well described, the underlying progression of 
pathology remains poorly understood.  Thus, the first goal of this work was to 
investigate the temporo-spatial progression of cellular pathology and behavioral 
deficits in the PPT1-/- mouse.  By gaining a better understanding of disease 
pathogenesis in a mouse model of INCL, we will be able to identify possible 
areas of therapeutic intervention for treatment of the human course of disease. 
Summary of characterization studies 
 The goals of the characterization studies in the PPT1-/- mice were two-
fold.  The initial characterization studies in the PPT1-/- mouse investigated the 
pathology of the forebrain and demonstrated that many of the pathological 
changes seen in patients with INCL were mirrored in the PPT1-/- mice.  
Therefore, the first goal of the characterization studies was to expand the 
forebrain characterization to investigate the temporal changes as they occur 
during disease progression.  These studies were carried out in collaboration with 
Jonathon Cooper’s Lab at Kings College – London (Kielar et al., 2007).   
The first pathologic change observed was astrocyte activation in both the 
cortex and thalamus of PPT1-/- mice at 3 mos. of age.  Subsequently, there was 
localized neuronal loss in thalamic nuclei that coincide with the regions where 
astrocyte activation occurred.  Beginning at 3-5 months of age, the thalamic 
regions affected by neuronal loss include the LGN, VPL/VPM, MGN, and Rt.  
Following neuronal loss in the thalamus, cortical atrophy and neuronal loss 
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occurred in the cortical relays of PPT1-/- mice at 5-7 mos. of age.  These regions 
included both the visual and somatosensory cortex, which receive reciprocal 
input from the thalamus. Neurodegeneration within both the thalamus and cortex 
correlated with an increase in microglia reactivity beginning at 5 mos. of age.  
Similarly, the onset of seizure activity and changes in the interictal EEG pattern 
occurred at 7 mos. of age, coinciding with neuronal loss and glial activation within 
the cortex and thalamus.  When taken together, this study identified a timeline for 
pathological changes within the forebrain.  First, astrocyte activation occurs 
followed by neuronal loss in thalamic nuclei.  Surprisingly, neurodegeneration 
and atrophy occur secondarily in the cortex to the thalamus.  Finally, widespread 
microglial activation and functional deficits occur in the PPT1-/- brain. 
The main goal of our characterization studies was to focus attention on the 
cerebellum (Macauley et al., 2009).  Motor deficits (Santavuori et al., 1974) and 
cerebellar atrophy (Haltia et al., 1973a; Haltia et al., 1973b) are well documented 
in patients with INCL, but no work was done to characterize the time course of 
pathology within the PPT1-/- mouse.  Therefore, we investigated the time course 
of cerebellar disease progression and motor deficits in the PPT1-/- mouse. 
Similar to the findings from the forebrain studies, the first pathological 
change observed in the PPT1-/- cerebellum was astrocyte activation.  As early as 
1 month of age, there was an increase in GFAP staining throughout the vermis.  
The intensity and distribution of GFAP staining increased as the mice aged.  
Subsequent to astrocyte activation, there was neuronal loss in the PPT1-/- 
cerebellum.  At 3 mos. of age, degenerating Purkinje cells were present within 
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the anterior lobes of the cerebellum.  There was a trend towards a decrease in 
total Purkinje cell number at 5 mos. with a significant loss in this population by 6 
mos. of age.  By 7 mos. of age, only 50% of all Purkinje cells remained in the 
PPT1-/- cerebellum.  Similarly, a significant decrease in granule cell number was 
also seen at 7 mos. of age, but not prior to this late stage time point. 
The scope of neurodegeneration occurring within the PPT1-/- cerebellum 
was visualized by silver degeneration staining.  In a 7 mo. old PPT1-/- brain, 
parasagittal bands of degenerating Purkinje cells filled the cerebellar cortex of 
the vermis and lateral hemispheres.  The molecular layer was littered with 
fragmented dendritic arbors associated with dying Purkinje cell neurons.  In 
addition to their dendritic arbors, the cerebellar white matter tracts displayed an 
intense staining suggesting the afferant and efferent fibers of the cerebellum 
were undergoing neurodegeneration. 
In addition to astrocyte activation and widespread neurodegeneration at 7 
mos. of age, there were pathological changes within the glial population of the 
PPT1-/- mouse.  There are numerous changes in the Bergmann glia suggestive 
of astrocyte dysfunction or death.  There are decreases or losses in markers like 
S100β and glutamine synthetase.  Furthermore, there are decreases in 
glutamate transporter staining, such as GLAST and to a lesser degree, GLT-1.  
The loss of these markers demonstrates a primary pathology intrinsic to the 
astrocyte that occurs in addition to early stage astrocyte activation.  In addition to 
the astrocytes, there is microglia activation beginning at 5 mos. of age as 
visualized by F4/80 staining.  The number, intensity and distribution of F4/80 
 91 
stained cells increase as the PPT1-/- mice age.  Moreover, there is a shift in the 
morphology of F4/80+ monocytes, from small, ramified microglia to larger, more 
amoeboid shaped macrophages.  Finally, a decrease in myelin is appreciable at 
7 mos. of age in the cerebellar white matter tracts of PPT1-/- mice.  The staining 
for myelin appears less intense and patchy at an end stage of disease. Taken 
together, these findings demonstrate that pathology within the PPT1-/- 
cerebellum is not limited to the neuronal population.  Rather, there is 
considerable pathology localized to the glial population, including the astrocytes, 
microglia, and oligodendrocytes, in the PPT1-/- mice. 
Finally, we sought to investigate how the changes in the underlying 
pathology correlated with motor deficits in the PPT1-/- mice.  A constant speed 
rotorod paradigm demonstrated significant motor deficits in the PPT1-/- 
beginning at 5 months of age.  The performance of the PPT1-/- mice further 
declined as the mice aged, with a nadir in performance by 7 months of age.  The 
alterations in motor function mirrored the Purkinje cell loss in the PPT1-/- mice.   
 Conclusions from characterization studies 
 The characterization studies provide a comprehensive time course of 
disease progression in the PPT1-/- mice.  These findings cause a shift in how we 
view the pathogenesis of INCL.  Historically, work performed on INCL patients at 
autopsy brought focus to certain pathological changes within the brain, including 
brain atrophy, cortical thinning, neuronal loss, and autofluorescent accumulation.  
Although these pathological changes are rightfully hallmarks of INCL, our work 
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demonstrates that many of these features occur at the end stage of disease and 
provide little insight into the evolution of pathology in this disorder.   
First, the dogma surrounding this disease is very neuro-centric and gives 
little attention to the profound glial involvement in this disease.  Our studies 
demonstrate that not only is astrocyte activation the first pathological change 
observed in INCL, but prominent glial involvement, including astrocytes, 
microglia, and oligodendrocytes, is a key component to this disease.  Thus, 
understanding the relative contributions of each cell type to disease pathology is 
important for the development and direction of therapies (see Future Directions).  
Secondly, given the data at autopsy and the functional deficits 
experienced by INCL patients, much of the focus for therapeutic intervention has 
centered on targeting the cortex.  Since neurodegeneration and atrophy in the 
cortex is a rather late stage phenomenon, intervention should occur earlier to 
prevent the disease progression and in areas affected at the onset of disease.  
Thus, interventions targeting astrocyte activation or the pathological changes in 
the thalamus would be better suited for early interventions to maximize 
therapeutic outcomes (see Future Directions).   
Finally, these characterization studies demonstrate both the extent and 
severity of disease in INCL.  Patients with INCL suffer from a complex set of 
clinical features, with extensive underlying pathology, which involves the majority 
of the CNS.  Thus, in order to properly treat these disorders, one form of targeted 
therapy will not be sufficient.  To provide patients with a therapeutic benefit, 
 93 
multiple therapies aimed at a variety of disease pathologies and targets must be 
employed (see Future Directions). 
Summary of findings from the GFAP-/-, Vimentin-/-, PPT1-/- mice 
 Based on the finding that the first pathological change observed in the 
PPT1-/- mouse was GFAP upregulation, therefore, we investigated whether 
astrocyte activation and GFAP upregulation was helpful or harmful to the CNS in 
INCL.  To accomplish this, we created the GFAP-/-, Vimentin-/-, PPT1-/- triple 
knockout (3KO) mouse by breeding the GFAP-/-, VImentin-/- double (2KO) 
mouse to the PPT1-/- mouse (Gupta et al., 2001; Pekny et al., 1999).  First, we 
investigated the effects of knocking out GFAP and Vimentin on disease 
parameters specific to INCL.  Interestingly, we found that PPT1-/- mice lacking 
GFAP and Vimentin displayed similar clinical features of INCL, but an 
accelerated time course when compared to PPT1-/-, 2KO, or WT mice.  The 3KO 
mice died earlier than the PPT1-/-, 2KO, and WT mice.  Moreover, the 3KO 
brains atrophied quicker than PPT1-/- mice and controls.  Both cortical atrophy 
and neurodegeneration was more severe in 3KO mice compared to PPT1-/- 
mice.  Thus, lacking the intermediate filament proteins, GFAP and Vimentin, 
increased the pervasiveness of the INCL phenotype in the PPT1-/- mouse. 
 One possible explanation for this accelerated phenotype is due to the 
influx of peripheral immune cells into the CNS of the 3KO mice.  Normally absent 
from the brain parenchyma, we found CD45-positive cells, or leukocytes, littering 
the neuraxis of the 3KO brains.  Staining with cell lineage specific markers 
illustrated the presence of CD3+ T cells and Iba-1+ macrophages and microglia 
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in the 3KO brains, cells normally absent from a healthy CNS.  Postulating that 
the trafficking of leukocytes into the CNS is due to a perturbation of the BBB, we 
investigated BBB integrity in the 3KO mice.  We found no gross disruption in the 
BBB of 3KO mice when compared with PPT1-/- or WT mice.  However, we did 
find structural alterations in the gliovascular unit of 3KO mice.  There was a 
redistribution of aquaporin 4 staining suggesting changes at the endfeet of 3KO 
astrocytes.  Furthermore, changes in PECAM staining demonstrated dysmorphic 
blood vessels in the 3KO brain.  Together, these changes demonstrated 
alterations in the gliovascular unit of 3KO mice.  Since the BBB is both a physical 
and molecular barrier in the CNS, we investigated the cytokine profiles in the 
3KO brains in comparison to PPT1-/-, 2KO, and WT brains.  In total, there were 
13 cytokines upregulated in the 3KO and PPT1-/- brains.  In every case, the 
cytokines elevation was greater in the 3KO brains in comparison to the PPT1-/- 
brains, in some cases up to a 40-fold increase compared to WT.  The molecules 
that were upregulated were largely pro-inflammatory molecules, chemokines for 
lymphocyte and monocyte chemotaxis, as well as stimulatory molecules for 
immune cell activation (Dong and Benveniste, 2001).  Thus, in the absence of 
the intermediate filament proteins, GFAP and Vimentin, there are signals within 
the PPT1-/- mouse brains that actively recruit peripheral immune cells into the 
CNS.  We hypothesize this leukocyte infiltration exacerbates disease, specifically 
the key features of INCL, in the 3KO mouse. 
Conclusions from the 3KO mice 
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 Our studies in the 3KO mice show that astrocyte activation, as defined by 
GFAP upregulation, is a protective process in INCL.  In the absence of GFAP 
and its copolymerizing IF, vimentin, the clinical features of INCL are the same in 
the PPT1-/- and 3KO mice, but increase in severity causing the mice to suffer an 
accelerated time course of disease.  Thus, we hypothesize that early stage 
astrocyte activation is protecting the CNS from injury.  Furthermore, our findings 
suggest that the upregulation of IFs is necessary to maintain the structural 
integrity of the blood brain barrier.  And in their absence, leukocyte infiltration 
from the periphery can occur and exacerbate CNS disease. 
 Although we described changes in the 3KO mice at an end stage of 
disease, a thorough characterization of disease progression in the 3KO brains 
should be performed (See Future Directions).  By investigating temporal changes 
in the 3KO mice, we could more thoroughly dissect the role astrocyte activation 
plays in INCL.  Specifically, if we are able to elucidate the function of astrocyte 
activation at early time points, we might be able to gain a better understanding of 
why astrocyte activation is the first change observed in INCL. 
 Beyond the role of astrocyte activation in INCL, these studies begin to 
help elucidate the function of IF upregulation and its relationship to the function of 
activated astrocytes in a model of chronic neurodegeneration. To date, little is 
known about how IF upregulation and changes in the astrocyte’s morphology 
relates to changes in cell function.  Increased GFAP expression is always used 
to demonstrate the presence of gliosis in CNS injury and disease, but little has 
been done to show the functional significance of GFAP upregulation in the 
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context of astrocyte activation.  Studies in the 3KO mice demonstrate a 
correlative role between IF upregulation and the functional changes associated 
with astrocyte activation.   
By using the PPT1-/- mouse as our model of disease, we are also 
investigating the role of astrocyte activation in a chronic, neurodegenerative 
disorder of the CNS.  Contrary to most of the work in the field, gliosis is normally 
studied in response to an acute injury, including models of tramautic brain injury, 
spinal cord lesion, acute infection, stroke, etc.  It is most likely that the manner 
with which the CNS responds to a focal, acute injury differs from its response to a 
disease that is chronic, progressive, and widespread.  Therefore, the 3KO mouse 
provides us with an excellent tool to study the mechanisms by which reactive 
astrocytes respond to a persistent, widespread disease (See Future Studies). 
 Finally, the 3KO mouse illustrates the dualistic nature of astrocyte 
activation.  Although astrocyte activation is overall a protective process in INCL, 
there are aspects of this inflammatory process that are harmful to the CNS.  For 
example, we demonstrated in the PPT1-/- mouse that cytokines responsible for 
leukocyte trafficking into the CNS are upregulated, while the 3KO model 
illustrated how leukocyte entry into the CNS correlates disease severity.  
Although gliosis is a process that adds protection to an injured brain (i.e. PPT1-/- 
brain), there are aspects of gliosis that are suboptimal (i.e. cytokine production) 
and can be targeted for therapeutic intervention (see Future Directions). 
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Future Directions    
Cell-specific contributions to INCL 
 Findings from the characterization studies performed in the PPT1-/- mice 
chronicled the scope of pathology observed within the PPT1-/- brains.  Although 
neurodegeneration was a widespread, pervasive phenomenon in the PPT1-/- 
brains, the extent of glial pathology had largely gone unappreciated until now.  
We demonstrated that astrocytes, microglia, and oligodendrocytes are all 
involved in the disease pathology of INCL.  Given that PPT1-deficiency is a 
global phenomenon in INCL and that glial cells are reported to express PPT1, 
perhaps it is not surprising that these cell types are equally as affected as 
neurons within the CNS.  However, to move towards a treatment of INCL, it 
would be beneficial to investigate the relative contribution of each cell type to 
disease pathology.  This would allow us to better target therapies to the correct 
cell lineage.   
Investigating the specific effects of cell lineages on INCL pathology is not 
easy to accomplish.  Attempting to isolate cell-specific effects in any disorder is 
difficult but there are unique benefits and problems when studying lysosomal 
storage diseases.  The main difficulty comes from the principle of “cross-
correction”. “Cross-correction” refers to the phenomenon in which lysosomal 
enzymes are expressed within the target cell as well as secreted and taken up by 
adjacent cells (Neufeld and Fratantoni, 1970).  This allows for one cell to act as 
an enzyme depot for all cell types within a microenvironment.  Although the 
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principle of “cross-correction” is beneficial for treatment of INCL and other LSDs, 
it complicates studying the cellular pathology in disease.  Therefore, traditional 
approaches using cell-specific promoters, transgenic technology, and the native 
PPT1 protein are not suitable for investigating the cellular mechanisms of 
disease in INCL.  
One way to circumvent the principle of “cross-correction” is to develop a 
means of sequestering lysosomal enzymes to prevent secretion.  This would 
allow for the specific correction of a target cell while keeping the diseased milieu 
intact.  Guarnieri and his colleagues (Guarnieri et al., 1993) identified a 35 amino 
acid peptide sequence, containing the transmembrane domain and cytoplasmic 
tail of lysosome-associated protein, LAMP-1, that is both necessary and sufficient 
for lysosomal trafficking and retention.  Therefore, it is possible to fuse a short 
LAMP1 peptide sequence to the carboxyl terminus of PPT1 to effectively create a 
lysosomal enzyme that is properly targeted to and retained by the lysosome 
(Marathe et al., 2000).  In fact, this approach was successfully used by Marathe 
et al (2000) to create a mouse model of Niemann-Pick Type B disease.   
 Using this approach to sequester the PPT1 enzyme within a specific cell 
type can then be used in concert with other standard gene transfer or transgenic 
approaches to investigate cellular mechanisms of disease.  By sequestering 
PPT1 within neurons or glia, it is possible to investigate the effects of selectively 
restoring function to a specific cell lineage on both the pathological and functional 
changes that occur in INCL.  This will provide valuable insights into the process 
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of disease pathogenesis as well as provide valuable targets for treatment of 
INCL. 
Further characterization of the 3KO mice 
 Our initial characterization studies in the 3KO mice provided insight into 
the role of astrocyte activation in INCL.  However, further work needs to be done 
to investigate the temporal changes in the 3KO mice.  Specifically, by clarifying 
the function of astrocyte activation at early time points, we can gain a better 
understanding of why astrocyte activation is the first change observed in INCL.  
Determining the timeline for the structural and molecular changes in the BBB 
would also provide insight into the role of activated astrocytes in INCL.  We 
demonstrated that increased expression of cytokines leads to an influx of 
peripheral immune cells into the CNS.  However, we failed to demonstrate what 
initial factors were responsible for cytokine upregulation and immune cell entry in 
the CNS.  By studying the 3KO pathology at earlier stages, we can uncover the 
true functions of activated astrocytes and work towards a better definition of what 
this process entails.   
Effective targeting of therapeutics in INCL 
 Our characterization studies in the PPT1-/- mouse established a time line 
of CNS pathology that challenged the current dogma in the field (Kielar et al., 
2007; Macauley et al., 2009).  First, we showed that astrocyte activation occurs 
early in the INCL, not later as was first hypothesized.  Secondly, we 
demonstrated that the thalamus is the first area to undergo neuronal loss, with 
degeneration in the cortex occurring secondarily.  Lastly, we illustrated that 
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pathological changes in INCL are not limited to a neuronal population, but also 
include glia.  Based on these findings, we need to alter the framework by which 
we develop and target therapies for INCL. 
 One of the most promising options for the treatment of LSDs is CNS-
directed gene therapy (Daly and Sands, 1998; Macauley and Sands, 2009a; 
Sands and Davidson, 2006; Sands and Haskins, 2008).  Since INCL and most 
other LSDs are due to a single enzyme deficiency, the simplest therapeutic 
approach is enzyme replacement therapy (ERT).  One way to ensure long-term, 
CNS-directed enzyme replacement therapy is through the use of viral vectors.  
Currently, adeno-associated virus (AAV) and lenti-viral vectors are touted as the 
best options for CNS-directed therapy due to their tropism, long-term expression, 
low immunogenicity, and transduction efficiencies.  However, many of the 
researchers investigating the use of viral vectors for the treatment of NCLs 
(Cabrera-Salazar et al., 2007; Griffey et al., 2004; Griffey et al., 2005; Griffey et 
al., 2006; Passini et al., 2006) are using vectors with a tropism for neuronal 
transduction (i.e. AAV-1, -2, and -5) (Burger et al., 2004).  Given the significant 
glial pathology in INCL and other forms of NCLs, findings from these therapy 
studies could mistakenly suggest that viral vectors are inefficient therapeutic 
tools.  Therefore, experiments need to be performed that directly compare the 
efficacy of glial- or neuronal-directed therapies for the treatment of INCL and 
other LSDs. 
  Given that the pathology encompasses the entire neuraxis in INCL, the 
task of directing therapies is quite challenging.  In mouse models of LSDs like 
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INCL, researchers are using novel therapies and methodologies in attempt to 
treat the brain in its entirety (Bobo et al., 1994; Chen et al., 2009; Daly et al., 
2001; Dodge et al., 2009).  Although this approach is ideal for disorders like 
INCL, there may be alternative ways to slow disease progression until a 
comprehensive treatment strategy is developed.  For example, the first area to 
display neuronal loss and glial activation is the thalamus, specifically the lateral 
geniculate nucleus (LGN).  Since previous research has demonstrated that early 
interventions increase therapeutic efficacy (Cabrera-Salazar et al., 2007), the 
thalamus should be targeted early to evaluate the effect of focal treatments on 
disease progression in INCL.  While safety and ethical issues surrounding the 
use of stem cell and gene therapies remain unanswered, direct infusions of 
recombinant enzyme into the CNS is a promising treatment for LSDs.  Therefore, 
preclinical experiments targeting the thalamus should be performed in the PPT1-
/- mouse to determine if a single infusion of recombinant enzyme, viral vectors, or 
stem cells can significantly delay or treat the clinical features of disease.   
Glial activation as a therapeutic target 
Based on our findings that cytokine levels are highly elevated in both the 
3KO mice and PPT1-/- brain due to glial activation, we hypothesized that 
disrupting the cytokine cascade is a possible target for therapeutic intervention.  
Our data demonstrate that when cytokines are increased to a certain threshold, 
leukocyte entry in the CNS occurs and the disease course is exacerbated.  We 
observed leukocyte entry into the CNS in the 3KO mice, but not the PPT1-/- 
mice, because of the relative cytokine elevation.  Therefore, by keeping the 
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cytokine levels stable, we believe we can delay the neuroinflammatory process 
response for accelerating the disease course of INCL.       
Recently, the laboratory of Dr. Martin Watterson developed a novel, small 
molecule called Minozac that targets the neuroimmune response generated by 
astrocytes and microglia (Hu et al., 2007; Ralay Ranaivo et al., 2006).  Minozac 
is non-toxic, bioavailable and able to cross the blood brain barrier (BBB).  It 
selectively acts on glia by knocking down pro-inflammatory cytokines that recruit 
circulating immune cells into the CNS.  When administered to mice, it showed 
positive results in models of Alzheimer’s(Ralay Ranaivo et al., 2006), 
EAE(Karpus et al., 2008), TBI(Lloyd et al., 2008; Somera-Molina et al., 2007), 
and epilepsy(Lloyd et al., 2008; Somera-Molina et al., 2007), all of which present 
with gliosis and neuroinflammation.  In each of the four diseases, treatment of 
Minozac reduced the number of activated astrocytes and microglia, decreased 
cytokine levels and improved behavioral deficits.  Of particular interest, in a kainic 
acid-induced model of epilepsy(Tian et al., 2005), researchers demonstrated that 
Minozac diminished the glial activation associated with seizure onset, which 
decreased the susceptibly of mice to future seizures.  Thus, the effects of 
Minozac in models of CNS disease show great promise, suggesting that Minozac 
is a good candidate for treating INCL.          
Combination therapy in INCL 
 Treatment for LSDs is as simple as it is complex.  Contrary to other CNS 
diseases like Alzheimer’s, Parkinson’s, or Huntington’s disease, the etiology of 
INCL is known.  Disease pathology in INCL is due to an enzyme deficiency and 
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thus, enzyme replacement therapy rescues the deficits.  Thus, in many ways, the 
treatment strategies for LSDs are quite simple and unsophisticated.  The problem 
arises in the scope of therapy necessary to treat those afflicted with these 
diseases.  Contrary to other CNS disorders, the disease pathology associated 
with INCL involves the entire neuraxis as well as many visceral tissues.  Thus, an 
effective treatment strategy must include targeting a variety of cell types in a 
diverse set of tissues.  It is unlikely that one therapy will be able to accomplish 
this feat in isolation.  Thus, we propose to use several therapies in combination 
for the treatment of INCL.            
The use of viral vectors to target PPT1 expression to the CNS is partially 
efficacious in newborn PPT1-/- mice(Griffey et al., 2004; Griffey et al., 2005).  
Although many histopathological parameters and behavioral deficits are 
improved, the therapeutic benefit is only partial.  Thus, future work needs to use 
gene therapy in combination with other possible treatments for INCL.  For 
example, Minozac, which targets the toxic effects of reactive gliosis, when used 
singularly this therapy will only be partially efficacious since the primary cause of 
INCL, a deficiency in PPT1, remains untreated.  Therefore, treating PPT1-/- mice 
with Minozac, in combination with other approaches might result in an additive or 
better yet, synergistic effect in patients with INCL.   
Furthermore, gene therapy and Minozac could be paired with a third drug 
for the treatment of INCL.  Cystagon, or phosphocysteamine, is responsible for 
disrupting thioester linkages in s-acylated proteins, a similar mode of action to 
the deficient enzyme, PPT1 (Lu and Hofmann, 2006; Zhang et al., 2001).  In vitro 
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studies demonstrated that Cystagon is capable of decreasing ceroid 
accumulation in lymphoblasts from INCL patients.  We have initiated preliminary 
studies using once daily injections of Cystagon into PPT1-/- mice.  The cystagon 
treatment is non-toxic, well tolerated, and results in some clinical benefit benefit 
early in disease progression.  Therefore, we hypothesize that Minozac in concert 
with Cystagon and gene therapy will result in an efficacious, synergistic treatment 
for INCL.  
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